Document:

Acquisition Agreement by and between Alphatec Holdings and HealthpointCapital

 EXHIBIT 10.2 
 ACQUISITION AGREEMENT 
 by and between 
 ALPHATEC HOLDINGS, INC. 
 and 
 HEALTHPOINTCAPITAL PARTNERS, L.P. 
 Dated as of September 27, 2006 

 THIS ACQUISITION AGREEMENT (this “Agreement”) is made and entered into as of
September 27, 2006, is by and between ALPHATEC HOLDINGS, INC., a Delaware corporation (“Issuer”), and HEALTHPOINTCAPITAL PARTNERS, L.P., a Delaware limited partnership (“HPC”). Issuer and HPC are sometimes
referred to herein each, individually, as a “Party” and, collectively, as the “Parties.” Certain terms are defined in Section 11.9 or 11.10. 
 WHEREAS, HPC owns 125 shares, with a nominal value of €100 each (the “Company Shares”), representing 100% of the share capital and 100% of the voting rights of HealthPoint (Luxembourg) I, a
Luxembourg société á responsabilité limiteé unipersonnelle with a share capital of 12,500 Euros (the “Company”); 
 WHEREAS, the Company owns 3,953,664 shares representing 33.1% of the outstanding shares (the “Scient’x Shares”) of Scient’x, a French société anonyme with a share
capital of 2,986,158 Euros (“Scient’x”); 
 WHEREAS, the Board of Directors of Issuer (the “Issuer Board”) has
determined that it is in the best interests of its stockholders for Issuer to acquire the Company upon the terms and subject to the conditions set forth in this Agreement; 
 WHEREAS, in furtherance of such acquisition, a wholly-owned indirect Subsidiary of the Issuer (the “Merger Sub”) will merge with and into the Issuer, with the Issuer continuing as the surviving
corporation (the “Issuer Subsidiary Merger”); 
 WHEREAS, in furtherance of such acquisition, Issuer agrees to acquire the Company Shares
held by HPC in exchange for shares of common stock, par value $0.0001 per share, of the Issuer or the successor registrant on consummation of the Issuer Subsidiary Merger (the “Shares”), upon the terms and subject to the conditions
of this Agreement; 
 WHEREAS, the Issuer Board has unanimously approved this Agreement and the transactions contemplated by this Agreement, including the
issuance of Shares to HPC in exchange for the Company Shares (collectively, the “Transaction”); 
 WHEREAS, prior to the execution and
delivery of this Agreement, certain officers and directors of Issuer, concurrently herewith, are entering into a stockholders support agreement, dated as of the date hereof, pursuant to which each has, among other things, upon the terms and subject
to the conditions set forth therein, irrevocably agreed to vote all Shares held by such individuals in favor of the transactions contemplated by this Agreement, and agreed to a standstill with respect to the Shares between the date hereof and the
Issuer Stockholders’ Meeting; 
 WHEREAS, concurrently with the execution and delivery of this Agreement, Issuer is entering into an agreement (the
“OC Acquisition Agreement”) with Olivier Carli (“Olivier Carli”) pursuant to which Issuer will issue Shares in exchange for all of the outstanding stock of the parent corporation of Scient’x held by Olivier
Carli (the “OC Exchange”); 
 WHEREAS, the Board has unanimously approved the transactions contemplated by
this Agreement; and 

 NOW, THEREFORE, in consideration of the foregoing and the mutual representations, warranties, covenants
and agreements herein contained, and for other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the Parties hereby agree as follows: 
 ARTICLE I 
 EXCHANGE OF SHARES 
 1.1 Exchange of Shares. Upon the terms and subject to the conditions contained in this Agreement, at the Closing HPC shall sell, assign, transfer,
convey and deliver to the Issuer, and the Issuer shall purchase, acquire and accept for delivery from HPC, 125 Company Shares, which represent all of the Company Shares beneficially owned by HPC. 
 1.2 Purchase Price. The aggregate purchase price (the “Purchase Price”) to be paid to HPC for the 125 Company Shares shall
be a number of Shares (the “Share Number”) equal to €44,174,808 divided by the Issuer Common Stock Price. For the avoidance of doubt, subject to the indemnity provisions of Article IX and Article X,
the Purchase Price paid hereunder to HPC shall not be subject to any purchase price adjustment whatsoever. 
 1.3 Fractional Shares.
No certificates or scrip representing fractional Shares shall be issued pursuant to this Agreement and such fractional share interests will not entitle the owner thereof to vote or to any other rights of a stockholder of Issuer. In lieu of such
fractional share interest, if any, HPC shall be paid an amount in cash (without interest and subject to the amount of any withholding taxes) equal to the product obtained by multiplying (i) such fractional share interest to which HPC would
otherwise be entitled by (ii) the Issuer Common Stock Price. 
 1.4 Payment of Purchase Price. At the Closing, Issuer shall pay
to HPC the Purchase Price as follows: 
 (a) Delivery to the Escrow Agent of a number of Shares (the “Escrow Shares”) equal
to 10% of the Share Number pursuant to the Escrow Agreement; 
 (b) Delivery to HPC of a number of Shares equal to the Share Number
less the Escrow Shares. 
 1.5 Closing Deliveries by HPC. 
 (a) At the Closing, HPC shall deliver, or cause to be delivered to the Issuer: 
 (i) a stock power or similar applicable transfer instrument for all of the Company Shares held by HPC, completed pursuant to the terms hereof, and any
other documents necessary for the transfer of good and marketable title to the Company Shares; and 
 (ii) the certificates and other
documents required to be delivered pursuant to Section 7.2. 

 (b) At the Closing, HPC shall cause the Company to make appropriate entries in the corporate books of the
Company and take any and all other actions required to register the consummation of the Transaction. 
 1.6 Closing Deliveries by the
Issuer. At the Closing, the Issuer shall deliver, or cause to be delivered, to HPC: 
 (a) stock certificates in the name of HPC
evidencing the number of Shares determined in accordance with Section 1.5; and 
 (b) the certificates and other documents required to
be delivered pursuant to Section 7.3. 
 1.7 The Parties agree that all actions required to be taken, and all deliverables required to
be delivered, at Closing shall be deemed to have been taken or delivered simultaneously and that unless and until all such actions have been taken and all such deliverables have been delivered. 
 1.8 Restricted Securities. The Shares shall be subject to restrictions on sale pursuant to a stockholders agreement, which shall include a lock-up
period of 180 days and incorporate the other terms and conditions set forth in the term sheet attached hereto as Schedule C (the “Stockholders Agreement”). Notwithstanding the 180 day lock up, Olivier Carli shall be entitled
to pledge 10% of his Shares. All certificates representing such Shares shall bear, in addition to any other legends required under applicable securities laws, the following legend: 
 “THE SHARES REPRESENTED BY THIS CERTIFICATE ARE SUBJECT TO A STOCKHOLDERS’ AGREEMENT AND MAY NOT BE TRANSFERRED, SOLD OR PLEDGED EXCEPT PURSUANT
TO THE TERMS AND CONDITIONS SET FORTH IN SUCH STOCKHOLDERS AGREEMENT. A COPY OF SUCH AGREEMENT MAY BE INSPECTED AT THE PRINCIPAL OFFICE OF THE ISSUER.” 
 1.9 Closing. Unless this Agreement shall have been terminated and the transactions contemplated by this Agreement abandoned pursuant to the provisions of ARTICLE VIII, and subject to the satisfaction or waiver,
as the case may be, of the conditions set forth in ARTICLE VII, the closing of the Transaction and the other transactions contemplated by this Agreement (the “Closing”) shall take place at 10:00 a.m. (Paris time) on a date to be
mutually agreed upon by the Parties (the “Closing Date”), which date shall be no later than the fifth Business Day after all the conditions set forth in ARTICLE VII (excluding conditions that, by their nature, cannot be satisfied
until the Closing) shall have been satisfied or waived in accordance with Section 8.4. The Closing shall take place at the offices of Weil, Gotshal & Manges, 2 rue de la Baume, 75008 Paris, or at such other location as is agreed
to by the Parties. For purposes of this Agreement, “Business Day” shall mean any day other than a Saturday or a Sunday on which banks are opened in both New York, New York, United States and Paris, France. 
 1.10 Taking of Necessary Action; Further Action. If, at any time and from time to time after the Closing, any further action is necessary or
desirable to vest in Issuer full right, title and possession over the Company Shares, HPC shall take, or cause to be taken all such lawful and necessary action as is consistent with this Agreement. 

 ARTICLE II 
 REPRESENTATIONS AND WARRANTIES REGARDING THE COMPANY 
 Except as set forth in the disclosure schedule
provided to Issuer on the date hereof and which is attached as Schedule A, as and accepted in writing by Issuer (the “Company Disclosure Schedule”), HPC, hereby represents and warrants to Issuer that the statements contained
in this ARTICLE II are true, complete and correct. The Company Disclosure Schedule shall be arranged in paragraphs corresponding to the numbered and lettered paragraphs contained in this ARTICLE II, and the disclosure in any paragraph shall be
deemed to be disclosed in each other paragraph in which it is reasonably appropriate for such matters to be disclosed. As used in this Agreement, a “Company Material Adverse Effect” means any change, event or effect that has a
material adverse effect on the business, assets (including, without limitation, intangible assets), financial condition, results of operations or reasonably foreseeable prospects of the Company and its Subsidiaries, taken as a whole, excluding any
changes, events or effects that are attributable to: (i) conditions that materially and adversely affect the general worldwide economy, which changes do not disproportionately affect the Company and its Subsidiaries; or (ii) conditions
that materially and adversely affect the industries in which the Company and its Subsidiaries compete, which changes do not disproportionately affect the Company and its Subsidiaries relative to other participants in such industry. For the avoidance
of doubt, decreases in the Company’s stock price in and of itself is not a Company Material Adverse Effect, provided that this sentence shall not preclude the other Party from asserting that the underlying cause of any such decrease in stock
price is a Company Material Adverse Effect. 
 2.1 Organization and Qualification. 
 (a) The Company is a Luxembourg société á responsabilité limiteé unipersonnelle, duly organized and validly
existing under the laws of Luxembourg. Scient’x is a French société anonyme, duly organized and validly existing under the laws of France registered and with the Registry of Commerce and Companies of Versailles, under
number RCS Versailles 348 366 733. Each of the Company and Scient’x is duly qualified or licensed as a foreign corporation to conduct business, and is in corporate good standing, under the laws of each jurisdiction where the character of the
properties owned, leased or operated by it, or the nature of its activities, makes such qualification or licensing necessary, except where the failure to be so qualified, licensed or in good standing, individually or in the aggregate, has not had
and would not reasonably be expected to have a Company Material Adverse Effect. Each of the Company and Scient’x has made available to Issuer true, complete and correct copies of its charter, of association or similar governing document, as
amended to date. Neither the Company nor Scient’x is in default under or in violation of any provision of its articles of association or similar governing document. The filings with the Registry of Commerce and Companies or other applicable
Governmental Authority of each of the Company and Scient’x are complete and 

 
up-to-date in all material respects; the current excerpts (or similar applicable document) from the Registry of Commerce and Companies (or other applicable
Governmental Authority) regarding each of the Company and Scient’x delivered to Issuer are true and accurate as of their respective dates. 
 (b) Neither the Company nor Scient’x is in a state of insolvency or unable to meet its payment obligations as they become due and is not and has never been subject to a judicial reorganization, judicial liquidation or voluntary
reorganization proceeding or any receivership or composition with creditors or collective bankruptcy proceedings provided for by the French or Luxembourg Law, nor have they requested an extension period pursuant to French or Luxembourg Law. The
Company has not been over the last five years, directly or indirectly a member of any partnership, joint venture, economic interest grouping, or any other organization or structure having unlimited liability. 
 (c) The books and records, including the stock transfer ledgers and the minutes of meetings, resolutions and written consents of the boards of directors
and stockholders, are up-to-date for each of the Company and Scient’x, have been fully maintained and contain true and accurate records in all material respects. There have been no meetings or proceedings of the board of directors (or similar
governing board) or the shareholders of either the Company or Scient’x, other than those reflected in the records of such Person. The minutes and other corporate records of each of the Company and Scient’x are accurate in all material
respects and up-to-date and true and complete copies of the minutes of Scient’x have been provided to the Issuer via the electronic data room of Scient’x. 
 2.2 Subsidiaries. 
 (a) The Company Disclosure Schedule sets forth a true, complete and correct list
of each direct or indirect Subsidiary of the Company (including Scient’x and all subsidiaries of Scient’x). 
 (b) Each direct or
indirect Subsidiary of the Company is a corporation duly organized, validly existing and in corporate good standing under the laws of the jurisdiction of its incorporation, and is duly qualified or licensed as a foreign corporation to conduct
business, and is in corporate good standing, under the laws of each jurisdiction where the character of the properties and other assets owned, leased or operated by it, or the nature of its activities, makes such qualification or licensing
necessary. The Company has made available to Issuer true, complete and correct copies of the Certificate of Incorporation, Bylaws or other charter or equivalent organizational documents of each of its direct and indirect Subsidiaries, each as
amended to date. 
 2.3 Capital Structure. 
 (a) The Company. 
 (i) The Company has a share capital of €12,500 consisting of 125 ordinary shares,
nominal value €100 per share. 

 (ii) As of the date hereof: (1) 125 ordinary shares are issued and outstanding and (2) there
are no warrants, convertible notes or other securities (including employee stock options) convertible or exchangeable for any shares of capital stock of the Company or rights thereto. Except as described in this paragraph, there are no shares of
voting or non-voting capital stock, equity interests or other securities of the Company authorized, issued, reserved for issuance or otherwise outstanding. 
 (iii) All outstanding ordinary shares are duly authorized, validly issued, fully paid, and not subject to, or issued in violation of, any kind of preemptive, subscription or any kind of similar rights. 
 (b) Scient’x. 
 (i) Scient’x has a
share capital of €2,986,158 consisting of 11,944,632 ordinary shares, nominal value €0.25 per share. 
 (ii) As of the date
hereof (i) 324,368 additional Scient’x Shares may be issued upon exercise of the options issued by Scient’x and Scient’x U.S.A. and outstanding under current employee stock option plan(s) (the “Scient’x Option
Plans”), and (ii) there are no warrants, convertible notes or other securities convertible or exchangeable for Scient’x Shares or any rights thereto. Except as described in this paragraph, there are no shares of voting or
non-voting capital stock, equity interests or other securities of Scient’x authorized, issued, reserved for issuance or otherwise outstanding. 
 (iii) All outstanding Scient’x Shares are, and all shares which may be issued pursuant to Scient’x Option Plans will be, when issued against payment therefore in accordance with the terms thereof, duly authorized, validly issued,
fully paid and non-assessable, and not subject to, or issued in violation of, any kind of preemptive, subscription or any kind of similar rights. 
 (c) Further Representations. 
 (i) Each of the Company and Scient’x satisfies all minimum capital requirements under French Law
or Luxembourg Law, as applicable. The transactions contemplated by this Agreement shall not increase the minimum capital requirements under French Law or Luxembourg Law, as applicable. 
 (ii) There are no bonds, debentures, notes or other indebtedness of the Company or of Scient’x having the right to vote (or convertible into
securities having the right to vote) on any matters on which shareholders of the Company or Scient’x, as applicable, may vote. Except as described in subsections (a)(ii), (a)(iii), (b)(ii) and (b)(iii) above, there are no outstanding
securities, options, warrants, calls, rights, commitments, agreements, arrangements or undertakings of any kind to which the Company or Scient’x is a party or bound obligating the Company or Scient’x, as applicable, to issue, deliver or
sell, or cause to be issued, delivered or sold, additional shares of capital stock or other voting securities of the Company or Scient’x, as applicable. 

 (iii) Each of the Company and Scient’x has previously made available to Issuer a true, complete and
correct list of all the outstanding options and warrants to purchase ordinary shares of the Company or Scient’x Shares, including: (i) the date of grant; (ii) the exercise price; (iii) the vesting schedule and expiration date;
and (iv) any other material terms, including, without limitation, any terms regarding the acceleration of vesting. 
 (iv) All ordinary
shares of the Company and all Scient’x Shares, and all options and warrants to purchase any such shares, were issued in compliance in all material respects with all applicable securities Laws. 
 (v) There are no outstanding contractual obligations of the Company or Scient’x to repurchase, redeem or otherwise acquire any shares of capital
stock (or options to acquire any such shares) or other security or equity interest of the Company or Scient’x, as applicable. There are no stock-appreciation rights, security-based performance units, phantom stock or other security rights
pursuant to which any Person is or may be entitled to receive any payment or other value based on the revenues, earnings or financial performance or other attribute of the Company or any of its Subsidiaries (including Scient’x). 
 (vi) There are no voting trusts, proxies or other agreements, commitments or understandings of any character to which the Company or any of its
Subsidiaries (including Scient’x) or, to the knowledge of HPC, any of the shareholders of the Company is a party or by which any of them is bound with respect to the issuance, holding, acquisition, voting or disposition of any shares of capital
stock or other security or equity interest of the Company or any of its Subsidiaries. 
 (vii) All of the issued and outstanding shares of
capital stock of, or other equity interests in, each Subsidiary of the Company are: (i) duly authorized, validly issued and fully paid; (ii) owned, directly or indirectly, by the Company (other than director’s qualifying shares) free and clear
of all liens, claims, security interests, pledges and encumbrances of any kind or nature whatsoever (collectively, “Liens”); and (iii) free of any restriction, including, without limitation, any restriction which prevents the
payment of dividends to the Company or any other Subsidiary of the Company, or which otherwise restricts the right to vote, sell or otherwise dispose of such capital stock or other ownership interest, other than restrictions under the Securities Act
of 1933, as amended (the “Securities Act”), and state securities laws. 
 2.4 Authority; No Conflict; Required
Filings. 
 No consent, approval, order or authorization of, or registration, declaration or filing with, any government, governmental, statutory,
regulatory or administrative authority, agency, body or commission or any court, tribunal or judicial body, whether U.S., French, Luxembourg, provincial, state, local or foreign (each, a “Governmental Authority”) is required by or
with respect to the Company or any of its Subsidiaries in connection with the execution and delivery of this Agreement or the consummation of the Transaction and other transactions contemplated hereby except for (i) such filings, notifications
and authorizations as may be required by the French Ministry of Economy and Finance or similar Luxembourg Governmental Authority, (ii) compliance with any applicable requirements of Council Regulation (EC) No. 139/2004 of the Council of
the European Union (the “EC Merger Regulation”) or (iii) compliance with any applicable requirements of any other French, Luxembourg or foreign antitrust laws or regulations. 

 2.5 Filings. 
 (a) To HPC’s knowledge, after having taken all reasonable measures to this effect, the annual report of the Company for the year ended December 31, 2005 (the “Company Annual Report”) did not
at the time it was filed (or, if later filed, amended or superseded, then on the date of such later filing) contain any untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary in order to make
the statements contained therein, in the light of the circumstances under which it was made, not misleading. 
 (b) To HPC’s knowledge,
after having taken all reasonable measures to this effect, neither the Document de base of Scient’x registered with the Autorité des marchés financiers on April 28, 2006, the note d’opération
registered with the Autorité des marchés financiers on May 29, 2006 nor the International Offering Memorandum of Scient’x dated May 29, 2006 (such three foregoing documents, the “Scient’x
Documents”) did not at the time it was filed (or, if later filed, amended or superseded, then on the date of such later filing) contain untrue statement of a material fact or omit to state a material fact required to be stated therein or
necessary in order to make the statements contained therein, in the light of the circumstances under which they were made, not misleading. 
 (c) Subsequent to the date of the issuance of the documents referred to in paragraphs (a) and (b) above, the Company has, to HPC’s knowledge after having taken all reasonable measures to this effect complied as to form in all
material respects with the applicable requirements of applicable Law relating to public disclosures, and any filings from and after such date did not, at the time it was filed, contain any untrue statement of a material fact or omit to state a
material fact required to be stated therein or necessary in order to make the statements contained therein, in the light of the circumstances under which they were made, not misleading. Taken together with the information and disclosures set forth
in the Company Disclosure Schedule, as of the date hereof of the Company Annual Report and the Scient’x Documents, as of the date hereof, contain all information that, if known to the public, would have an impact on the trading price of the
Company Shares. 
 2.6 Agreements, Contracts and Commitments. 
 (a) Issuer has been provided via the Scient’x electronic data room with copies of all contracts entered into by Scient’x or its Subsidiaries
that would come within the definition of “Material Contracts” under Item 601(b)(10) of Regulation S-K promulgated under the Securities Act (the “Scient’x Material Contracts”). 
 (b) Each Scient’x Material Contract is valid and binding on the respective parties thereto and is in full force and effect. Neither
Scient’x nor any of its Subsidiaries is in breach of, or default under, any Scient’x Material Contract. 

 ARTICLE III 
 REPRESENTATIONS AND WARRANTIES REGARDING HPC. 
 HPC hereby represents and warrants to the Issuer that:

 3.1 Authority Relative to This Agreement. This Agreement has been duly and validly executed and delivered by HPC and, assuming the
due authorization, execution and delivery by the Issuer, constitutes a legal, valid and binding obligation of HPC, enforceable against HPC in accordance with its terms, subject only to: (i) the effects of bankruptcy, insolvency, fraudulent
conveyance, reorganization, moratorium and other similar laws relating to or affecting the enforcement of creditors’ rights generally; (ii) general equitable principles (whether considered in a proceeding in equity or at law); and
(iii) an implied covenant of good faith and fair dealing (collectively, the “Equitable Exceptions”). 
 3.2 No
Conflict. 
 (a) The execution and delivery of this Agreement by HPC do not, and the performance of this Agreement by HPC will not result
in any breach of, or constitute a default (or an event which, with notice or lapse of time or both, would become a default) under, or give to others any right of termination, amendment, acceleration or cancellation of, or result in the creation of a
Lien on any of the Company Shares owned by HPC pursuant to, any note, bond, mortgage, indenture, contract, agreement, lease, license, permit, franchise or other instrument or obligation to which HPC is a party or by which HPC or the Company Shares
owned by HPC are bound or affected, except for any such conflicts, violations, breaches, defaults or other occurrences which would not reasonably be expected, individually or in the aggregate, to prevent or materially delay consummation of the
Transaction or otherwise prevent or materially delay HPC from performing its obligations under this Agreement. 
 (b) The execution and
delivery of this Agreement by HPC do not, and the performance of this Agreement by HPC will not, require any consent, approval, authorization or permit of, or filing with or notification to, any Governmental Authority on the part of HPC, except for
(i) compliance with the EC Merger Regulation, or any French or Luxembourg antitrust regulation, as applicable or (ii) the pre-merger notification and waiting period requirements of the HSR Act. 
 3.3 Title to the Company Shares. As of the date hereof, HPC is the record and beneficial owner of the number of Company Shares set forth in
Section 1.1. Such Company Shares are all the securities of the Company owned both of record or beneficially, by HPC. The Company Shares owned by HPC are now and, at all times prior to the Closing will be, owned free and clear of all Liens,
other than any Liens created by this Agreement. 
 3.4 U.S. Tax Matters. HPC has not entered into any binding commitment to sell,
exchange, transfer, distribute or otherwise dispose of all or any portion of the Shares and is under no legal obligation to do so. 

 3.5 Investment Intent. 
 (a) HPC represents and warrants to Issuer that it (i) is acquiring the Shares for investment for its own account, and not with a view to, or for sale
in connection with, any distribution thereof, (ii) either alone or together with its advisors, has sufficient knowledge and experience in financial and business matters so as to be capable of evaluating the merits and risks of his investment in
the Shares and is capable of bearing the economic risks of such investment, (iii) is an “accredited investor” as defined in Rule 501(a) of Regulation D under the Securities Act, and (iv) understands and acknowledges that the
Shares have not been registered under the Securities Act and, unless so registered, may not be offered, sold, transferred, or otherwise disposed of except pursuant to an exemption from, or in a transaction not subject to, the registration
requirements of the Securities Act. 
 (b) HPC understands and acknowledges that the Shares will be inscribed with the following legends, or
another legend to the same effect and agrees to the restrictions set forth therein: 
 “The shares represented by this certificate have
not been registered under the Securities Act of 1933, as amended, in reliance upon an exemption from the registration requirements of such Act. The shares represented by this certificate may not be sold or otherwise transferred, nor will an assignee
or endorsee hereof be recognized as an owner of the shares by the issuer unless (i) a registration statement under the Securities Act of 1933 with respect to the shares and the transfer thereof shall then be in effect, or (ii)in the opinion of
counsel reasonably satisfactory to the Issuer, the shares are transferred in a transaction which is exempt from the registration requirements of the Securities Act of 1933, as amended.” 
 3.6 Surgiview SAS. HPC represents that the purchase by Surgiview SAS of certain assets owned by Eurosurgical SA together with the purchase by
Scient’x of Surgiview SA have been completed in compliance with French Law. 
 ARTICLE IV 
 REPRESENTATIONS AND WARRANTIES OF ISSUER 
 Except as set forth in the disclosure schedule provided to HPC on the date hereof, which is attached as Schedule B, and accepted in writing by HPC (the “Issuer Disclosure Schedule”), the Issuer represents and
warrants to HPC as follows: 
 4.1 Organization. Issuer is a corporation duly incorporated, validly existing and in corporate and tax
good standing under the laws of its jurisdiction of incorporation. 
 4.2 Capital. The authorized capital stock of Issuer consists of
200,000,000 Shares and 20,000,000 shares of preferred stock, par value $0.0001 per share (the “Issuer Preferred Stock”). At the close of business on September 25, 2006, (i) 34,799,022 Shares were issued and outstanding,
(ii) no Shares were held by Parent in its treasury, (iii) 6,400,000 Shares were 

 
reserved for issuance under the Issuer’s Amended and Restated 2005 Employee Director and Consultant Stock Plan (collectively, the “Issuer Stock
Plans”) (of which 661,613 Shares were subject to outstanding options to purchase Shares granted under the Issuer Stock Plans), and (iv) 3,333,201 shares of Issuer Preferred Stock were issued and outstanding. All Shares deliverable pursuant
to this Agreement have been duly authorized (subject to obtaining the requisite approval of the Issuer Transactions by the stockholders of the Issuer) and, when issued as contemplated by this Agreement, will be validly issued, fully paid,
nonassessable and free of preemptive rights. 
 4.3 Authority; No Conflict; Required Filings. 
 (a) Issuer has all requisite corporate power and authority to execute and deliver this Agreement, to perform its obligations hereunder and to consummate
the Transaction and other transactions contemplated hereby. The execution and delivery of this Agreement, the performance of its obligations hereunder and the consummation of the Transaction and other transactions contemplated hereby, have been
duly authorized by all corporate action on the part of Issuer and no other corporate proceedings are necessary. 
 (b) This Agreement has
been duly executed and delivered by Issuer and constitutes a valid and binding obligation of Issuer, enforceable against it in accordance with its terms, subject only to the Equitable Exceptions. 
 (c) The execution and delivery of this Agreement do not, and the performance by Issuer of its obligations hereunder and the consummation of the
Transaction and other transactions contemplated hereby will not, conflict with or result in any violation of, or default (with or without notice or lapse of time, or both) under: (i) its Certificate of Incorporation, Bylaws or other equivalent
organizational documents; (ii) subject to the governmental filings and other matters referred to in paragraph (d) below, any (A) permit, license, franchise, statute, law, ordinance or regulation or (B) judgment, decree or order,
in each case applicable to it, or by which any of its properties or assets may be bound or affected; or (iii) any loan or credit agreement, note, bond, mortgage, indenture, contract, agreement, lease or other instrument or obligation to which
it is a party or by which its properties may be bound or affected, except, in the case of clauses (ii) or (iii) above, for any such conflicts, violations, defaults or other occurrences, if any, that could not, individually or in the
aggregate, reasonably be expected to impair the ability of the Parties to consummate the Transaction on a timely basis. 
 (d) No consent,
approval, order or authorization of, or registration, declaration or filing with, any Governmental Authority is required by or with respect to Issuer in connection with the execution and delivery of this Agreement or the consummation of the
Transaction or other transactions contemplated hereby except for: (i) the Required Issuer Vote; (ii) the filing of the Registration Statement and its declaration of effectiveness by the SEC; (iii) the filing of the certificate of
merger in Delaware in respect of the Issuer Subsidiary Merger; (iv) filings and consents in respect of the listing of the Shares to be issued in connection with the Transaction; and (ii) such consents, approvals, orders or authorizations,
or registrations, declarations or filings which, if not obtained or made, could not reasonably be expected to impair the ability of the Parties to consummate the Transaction on a timely basis. 

 4.4 Issuer Prospectus. The Prospectus filed by Issuer with the SEC on June 5, 2006
(i) at the time filed complied as to form in all material respects with the applicable requirements of the Securities Act and/or the Exchange Act, as the case may be and (ii) did not at the time it was filed nor, except as set forth in a
disclosure schedule hereto or in filings with the SEC subsequent to that date, would it if dated and delivered on the date hereof, contain any untrue statement of a material fact or omit to state a material fact required to be stated therein or
necessary in order to make the statements contained therein, in the light of the circumstances under which they were made, not misleading. 
 4.5 Compliance with Exchange Act. Subsequent to June 5, 2006, the Issuer has complied in all material respects with the applicable requirements of the Securities Act and/or Exchange Act, as the case may be, and any filings from
and after such date and prior to the date hereof did not, at the time it was filed, contain any untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary in order to make the statements contained
therein, in the light of the circumstances under which they were made, not misleading. 
 4.6 Organization, qualification, subsidiaries,
capital structure. The information contained in the Issuer Prospectus plus any documents filed subsequently in accordance with the Securities Act and the Exchange Act, taken as a whole, comparable to the information concerning the Company and
its Subsidiaries in Sections 2.1, 2.2 and 2.3 is true and correct. 
 4.7 Agreements, Contracts and Commitments 
 (a) HPC has been provided via the Issuer filings with the SEC or the Issuer electronic data-base with copies of all contracts entered into by the Issuer
or its Subsidiaries that come within the definition of “Material Contracts” under Item 601(b)(10) of Regulation S-K promulgated under the Securities Act (the “Issuer Material Contracts”). 
 (b) Each Issuer Material Contract is valid and binding on the respective parties thereto and is in full force and effect. Neither the Issuer nor any of
its Subsidiaries is in breach of, or default under, any Issuer Material Contract. 
 4.8 Merger Sub. From the date of incorporation of
Merger Sub to the Closing, Issuer will own beneficially of record all the outstanding capital stock of Merger Sub. Merger Sub will be formed solely for the purpose of engaging in the Issuer Transactions and will engage in no other business
activities and will conduct its operations only as contemplated hereby. 
 ARTICLE V 
 CONDUCT OF BUSINESS PENDING THE TRANSACTION 
 5.1 Conduct of Business Pending the Transaction. HPC covenants and agrees to cooperate with Olivier Carli in carrying out all his obligations under Section 5.1 of the OC Acquisition Agreement. 

 ARTICLE VI 
 ADDITIONAL AGREEMENTS 
 6.1 Reasonable Efforts; Further Assurances. 
 (a) Issuer shall, and HPC shall use reasonable efforts to cause the Company to, use their respective commercially reasonable efforts to satisfy or cause
to be satisfied all of the conditions precedent that are set forth in ARTICLE VII, as applicable to each of them. Each Party, at the reasonable request of the other, shall execute and deliver such other instruments and do and perform such other acts
and things as may be necessary or desirable for effecting completely the consummation of the Transaction and other transactions contemplated by this Agreement. 
 (b) Subject to the terms and conditions hereof, Issuer shall, and HPC shall use reasonable efforts to cause the Company to, use their respective commercially reasonable efforts to take, or cause to be taken, all
action and to do, or cause to be done, all things necessary, proper or advisable to consummate and make effective, in the most expeditious manner practicable, the Transaction and other transactions contemplated by this Agreement including, without
limitation, using their respective commercially reasonable efforts: (i) to obtain prior to the Closing Date all licenses, certificates, permits, consents, approvals, authorizations, qualifications and orders of Governmental Authorities and
parties to contracts with the Company or its Subsidiaries as are necessary for the consummation of the transactions contemplated hereby; (ii) to effect all necessary registrations and filings required by any Governmental Authority (in
connection with which Issuer shall, and HPC shall cause the Company to, cooperate with each other in connection with the making of all such registrations and filings, including, without limitation, providing copies of all such documents to the
non-filing party and its advisors prior to the time of such filing and, if requested, will accept all reasonable additions, deletions or changes suggested in connection therewith); (iii) to furnish to each other such information and assistance
as reasonably may be requested in connection with the foregoing; and (iv) to lift, rescind or mitigate the effects of any injunction, restraining order or other ruling by a Governmental Authority adversely affecting the ability of any Party to
consummate the Transaction or other transactions contemplated hereby and to prevent, with respect to any threatened or such injunction, restraining order or other such ruling, the issuance or entry thereof. 
 6.2 Notification of Certain Matters. 
 (a) HPC shall give prompt notice to Issuer, and Issuer shall give prompt notice to HPC, of the occurrence or non-occurrence of (i) any event, the occurrence or non-occurrence of which could reasonably be expected to result in any
representation or warranty contained in this Agreement to be untrue or inaccurate and (ii) any failure of HPC or Issuer, as the case may be, to comply with or satisfy any covenant, condition or agreement to be complied with or satisfied by it
hereunder; provided, however, that the delivery of any notice pursuant to this Section 6.2(a) shall not limit or otherwise affect the remedies available hereunder to the Party receiving such notice. 

 (b) HPC shall give prompt notice to Issuer, and Issuer shall give prompt notice to HPC of (i) any
notice or other communication from any Person alleging that the consent of such Person is or may be required in connection with the Transaction or other transactions contemplated by this Agreement; (ii) any notice or other communication from
any Governmental Authority in connection with the Transaction or other transactions contemplated by this Agreement; (iii) any litigation, relating to or involving or otherwise affecting the Company or any of its Subsidiaries or Issuer that
relates to the Transaction or other transactions contemplated by this Agreement; (iv) the occurrence of a default or event that, with notice or lapse of time or both, will become a default under either a Scient’x Material Contract or an
Issuer Material Contract; and (v) any change that would be considered reasonably likely to result in a Company or Issuer Material Adverse Effect, as the case may be, or is likely to impair the ability of either Issuer or the Company to
consummate the transactions contemplated by this Agreement. 
 (c) Issuer and HPC shall not, and HPC shall cause the Company not to take any
action or fail to take any reasonable action permitted by this Agreement if such action or failure to take action could reasonably be expected to result in any of the conditions to the Closing set forth in ARTICLE VI of this Agreement not being
satisfied as of the Closing Date. 
 6.3 Public Announcements. Except as otherwise required by applicable law, court process or as
provided elsewhere herein, prior to the Closing or the earlier termination of this Agreement pursuant to ARTICLE VIII, neither the Company nor Issuer shall, nor shall permit any of its Subsidiaries to, issue or cause the publication of any
press release or other public announcement with respect to the Transaction or other transactions contemplated by this Agreement without the consent of the other Party, which consent shall not be unreasonably withheld, conditioned or delayed.

 6.4 Antitrust Laws. 
 (a) Each Party shall, and HPC shall cause the Company to (i) make the filings required of it or any of its affiliates under any applicable merger control regulations in connection with this Agreement and the transactions contemplated
by this Agreement no later than the tenth Business Day following the date hereof, (ii) comply at the earliest practicable date, and after consultation with, the Issuer with any request for additional information or documentary material received
by it or any of its affiliates from any competent Governmental Authority, (iii) cooperate with one another in connection with any filing under relevant merger control regulations, if required, and in connection with resolving any investigation
or other inquiry concerning the transactions contemplated by this Agreement initiated by any competent Governmental Authority, (iv) use its reasonable efforts to obtain the approvals and consents required for the consummation of the
transactions contemplated by this Agreement and (v) use its reasonable efforts to cause the waiting periods under relevant merger control regulations, if applicable, to terminate or expire no later than 30 days after the date of this Agreement.

 (b) None of the Parties will, and HPC shall cause the Company not to, without the prior written consent of the Issuer, take or fail to
take any action which would reasonably be expected to materially impede, interfere with or delay any approval by any Governmental Authority with respect to the transactions contemplated by this Agreement. 

 (c) Each Party shall promptly inform the other Party of any material communication made to, or received
by such Party from, any Governmental Authority regarding any of the transactions contemplated by this Agreement. 
 (d) Notwithstanding
anything herein to the contrary, the filing fees under any applicable merger control regulations shall be borne by the Issuer. 
 6.5
Registration Statement. 
 (a) As promptly as practicable after the execution of this Agreement, Issuer, with the timely cooperation
and assistance of the Company, Scient’x and HPC, shall prepare and file with the SEC a registration statement on Form S-4 to register the Shares to be issued in connection with the Issuer Subsidiary Merger, which shall include a combined proxy
statement and prospectus relating to the meeting of Issuer’s stockholders (the “Issuer Stockholders’ Meeting”) to be held to consider approval of the Issuer Transactions and the OC Exchange (such registration statement, as
amended or supplemented, the “Registration Statement”). HPC shall cause the Company to provide all information regarding HPC, the Company and Scient’x as may reasonably be requested by Issuer for inclusion in the Registration
Statement. As promptly as practicable after the Registration Statement shall have been declared effective by the SEC, Issuer shall mail the proxy statement and prospectus contained therein to its stockholders. 
 (b) If, at any time prior to the Issuer Stockholders’ Meeting, any event or circumstance relating to Issuer, HPC, the Company or Scient’x, or
any of their respective affiliates, shareholders, officers or directors should be discovered by Issuer, the Company, Scient’x or HPC, as the case may be, which should be set forth in an amendment or supplement to the Registration Statement so
that the Registration Statement would not include any untrue statement of a material fact or fail to state any material fact required to be stated therein or necessary in order to make the statements therein, in light of the circumstances under
which they were made, not misleading, the Issuer, the Company or HPC (on behalf of itself, the Company and Scient’x, as the case may be, shall promptly inform the other parties. Subject to Section 6.5(d), as promptly as practicable after
discovering such event or circumstance or being so informed, Issuer, with the timely cooperation and assistance of HPC, the Company and Scient’x shall prepare and file with the SEC an amendment or supplement to the Registration Statement
containing a description of such event or circumstance and disseminate such amendment or supplement to the Registration Statement to the stockholders of Issuer. 
 (c) Issuer covenants that no amendment or supplement to the Registration Statement will be made by Issuer without the approval of HPC (such approval not to be unreasonably withheld or delayed). Issuer will advise HPC,
as promptly as practicable after it receives notice thereof, of any request by the SEC for amendment of the Registration Statement or comments thereon and responses thereto or requests by the SEC for additional information. 
 (d) Issuer covenants that the information supplied by Issuer for inclusion in the Registration Statement shall not, at (i) the time the proxy
statement/prospectus included in the Registration Statement (or any amendment thereof or supplement thereto) is first mailed to the shareholders of Issuer, (ii) the time of the Issuer Stockholders’ Meeting and (iii) the Closing,
contain any untrue statement of a material fact or fail to state any material fact required to be 

 
stated therein or necessary in order to make the statements therein, in light of the circumstances under which they were made, not misleading. All documents
that Issuer is responsible for filing with the SEC in connection with the Issuer Stockholders’ Meeting, the Transaction or the other transactions contemplated by this Agreement will comply as to form and substance in all material aspects with
the applicable requirements of the Securities Act and the rules and regulations thereunder and the Exchange Act and the rules and regulations thereunder. 
 (e) HPC covenants that the information supplied by him for inclusion in the Registration Statement shall, to his knowledge, not, at (i) the time the proxy statement/prospectus included in the Registration
Statement (or any amendment thereof or supplement thereto) is first mailed to the shareholders of Issuer, (ii) the time of the Issuer Stockholders’ Meeting and (iii) the Closing, contain any untrue statement of a material fact or fail
to state any material fact required to be stated therein or necessary in order to make the statements therein, in light of the circumstances under which they were made, not misleading. For the avoidance of doubt, the indemnification provided in
Article IX shall be the exclusive remedy of the Issuer against HPC in respect of any breach of this covenant. 
 6.6 Issuer
Stockholders’ Meeting. Issuer shall call and hold the Issuer Stockholders’ Meeting as promptly as practicable for the purpose of voting upon the approval of Issuer Transactions and the OC Exchange. Issuer shall use its reasonable best
efforts to hold the Issuer Stockholders’ Meeting as soon as practicable after the date on which the proxy statement/prospectus included in the Registration Statement is mailed to the stockholders of Issuer. Issuer shall use its reasonable best
efforts to solicit from its stockholders proxies in favor of the approval of Issuer Transactions and the OC Exchange, and shall use its reasonable best efforts to secure the required vote or consent of its stockholders, and the affirmative vote or
consent of holders of a majority of the outstanding shares of each class of capital stock of Issuer entitled to vote on the transactions contemplated by this Agreement, exclusive of shares held by HCP and its affiliates (the “Required Issuer
Vote”). Nothing contained in this Section 6.6 shall prevent the Issuer Board from acting in accordance with applicable Delaware corporate Law. 
 6.7 Tender Offer. 
 (a) Promptly after the Closing, Issuer shall commence a tender offer or any other
applicable procedure pursuant to French Law to purchase all Company Shares not purchased from Olivier Carli or Christian Carli under the OC Acquisition Agreement or from HPC hereunder (the “Tender Offer”) and shall comply with all
of the requirements of the Règlement général de l’Autorité des marchés financiers. HPC covenants to provide such reasonable assistance with the Tender Offer as the Issuer may request. Issuer shall make
all necessary filings required under applicable Law in connection with the Tender Offer and will cause any such documents to be disseminated to the holders of the Company Shares as and to the extent required by applicable Law. In connection with the
Tender Offer, Issuer shall give all holders of options issued pursuant to Scient’x Option Plans the choice, to the extent permitted by applicable Law, to retain such option and enter into an agreement with Issuer that will enable such holder to
exchange any Scient’x Shares issuable upon exercise of such option for Shares. 
 (b) Issuer covenants that the information
supplied by Issuer for inclusion in the documentation to be provided in connection with the Tender Offer (the “Tender Offer 

 
Documentation”) will not, to its knowledge, after having taken all reasonable measures to this effect, contain any untrue statement of a material
fact or fail to state any material fact required to be stated therein or necessary in order to make the statements therein, in light of the circumstances under which they were made, not misleading. 
 (c) HPC covenants that the information supplied by him for inclusion in the Tender Offer Documentation shall, to his knowledge, after having taken all
reasonable measures to this effect, contain any untrue statement of a material fact or fail to state any material fact required to be stated therein or necessary in order to make the statements therein, in light of the circumstances under which they
were made, not misleading. For the avoidance of doubt, the indemnification provided in Article IX shall be the exclusive remedy of the Issuer against HPC. 
 ARTICLE VII 
 CONDITIONS TO CLOSING 
 7.1 Conditions to Obligations of Each Party to Effect the Transaction. The obligations of each Party to effect the Transaction and consummate the
other transactions contemplated hereby shall be subject to the satisfaction at or prior to the Closing of the following conditions, any of which may be waived in writing by the Party entitled to the benefit thereof, in whole or in part, to the
extent permitted by the applicable law: 
 (a) No Injunctions or Restraints; Illegality. No temporary restraining order, preliminary or
permanent injunction or other order (whether temporary, preliminary or permanent) issued by any court of competent jurisdiction, or other legal restraint or prohibition shall be in effect which prevents the consummation of the Transaction and the
other transactions contemplated herein on substantially identical terms and conferring upon the Parties substantially all the rights and benefits as contemplated herein, nor shall any proceeding brought by any Governmental Authority, domestic or
foreign, seeking any of the foregoing be pending, and there shall not be any action taken, or any law, regulation or order enacted, entered, enforced or deemed applicable to the Transaction and the other transactions contemplated herein, which makes
the consummation of the Transaction and the other transactions contemplated herein on substantially identical terms and conferring upon the Parties substantially all the rights and benefits as contemplated herein illegal; 
 (b) Antitrust. Issuer shall have obtained all Antitrust Clearances; and 
 (c) Registration Statement. The Registration Statement shall have been declared effective by the SEC and no stop order suspending such
effectiveness shall have been issued and no proceedings for that purpose shall have been initiated or threatened by the SEC. 
 7.2
Additional Conditions to Obligations of Issuer. The obligations of Issuer to effect the Transaction are also subject to the following conditions, any and all of which may be waived in writing by Issuer, in whole or in part, to the extent
permitted by the applicable law: 
 (a) Representations and Warranties. The representations and warranties contained in ARTICLE II and
ARTICLE III shall be true and correct as of the Closing Date as though made on and as of the Closing, except (x) that those representations and warranties which address 

 
matters only as of a particular date shall be true and correct on and as of such particular date and (y) where the failure to be so true and correct has
not had a Company Material Adverse Effect; and Issuer shall have received a certificate to such effect signed by HPC. 
 (b) Agreements
and Covenants. HPC shall have performed or complied in all material respects with all agreements and covenants required by this Agreement to be performed or complied with by it on or prior to the Closing. Issuer shall have received a certificate
to such effect signed by HPC. 
 (c) No Material Adverse Effect. From and after the date hereof, there shall not have occurred
any event or occurrence and no circumstance shall exist which, alone or together with any one or more other events, occurrences or circumstances has had, is having or could reasonably be expected to result in a Company Material Adverse Effect.

 (d) Financing. Issuer shall have received at least $65 million under the Financing Letter or any Substitute Financing, in either
such case on terms and conditions reasonably acceptable to the Issuer. 
 (e) Escrow Agreement. HPC and the Escrow Agent shall have
executed and delivered to Issuer the Escrow Agreement. 
 (f) OC Exchange. The OC Exchange shall have occurred. 
 (g) Issuer Subsidiary Merger. The Issuer Transactions shall have been approved, the Required Issuer Vote shall have been obtained and the
Issuer Subsidiary Merger shall have been consummated. 
 (h) Stockholders Agreement. The parties hereto shall have entered into the
Stockholders Agreement. 
 (i) Withholding Certificates. HPC shall have delivered to Issuer any and all valid and executed
documentation reasonably requested by Issuer to avoid U.S. withholding tax obligations on Issuer’s payment of the Purchase Price. 
 (j)
French Expert Independent Report. HPC shall cooperate in the timely appointment by the Board, in connection with the Tender Offer, of an expert independant pursuant to Titre VI of Livre II of the réglement
general de l’Autorité des marches financiers and in having the report of such expert communicated to the Issuer at least 5 trading days prior to the Issuer Stockholders’ Meeting. 
 7.3 Additional Conditions to Obligations of HPC. The obligation of HPC to effect the Transaction is also subject to the following conditions, any
and all of which may be waived in writing by HPC, in whole or in part, to the extent permitted by the applicable law: 
 (a)
Representations and Warranties. The representations and warranties of Issuer contained ARTICLE IV shall be true and correct as of the date hereof and as of the Closing Date as though made and on and as of the Closing, except (x) that
those representations and warranties which address matters only as of a particular date shall be true and correct on and as of such 

 
particular date and (y) where the failure to be so true and correct has not had an Issuer Material Adverse Effect, and HPC shall have received a
certificate to such effect signed by the President of Issuer. 
 (b) Agreements and Covenants. Issuer shall have performed or complied
with all agreements and covenants required by this Agreement to be performed or complied with by them on or prior to the Closing, and HPC shall have received a certificate to such effect signed by the President of Issuer. 
 (c) No Material Adverse Effect. From and after the date hereof, there shall not have occurred any event or occurrence and no circumstance
shall exist which, alone or together with any one or more other events, occurrences or circumstances has had, is having or could reasonably be expected to result in an Issuer Material Adverse Effect. 
 (d) Certificate. Issuer shall have delivered to HPC and the Company (i) a copy of the resolutions of the Issuer Board and the Issuer
Stockholders’ Meeting authorizing the Issuer Transactions, and (ii) its certificate of incorporation and by-laws, in each case certified as true, complete and correct by its chief executive officer. 
 (e) Escrow Agreement. Issuer and the Escrow Agent shall have executed and delivered to HPC the Escrow Agreement. 
 ARTICLE VIII 
 TERMINATION, AMENDMENT
AND WAIVER 
 8.1 Termination. This Agreement may be terminated and the Transaction and other transactions contemplated hereby may
be abandoned at any time prior to the Closing: 
 (a) by mutual written consent of the Parties; 
 (b) by either Issuer or HPC if the OC Acquisition Agreement is terminated pursuant to its terms; 
 (c) by either Issuer or HPC, if a Governmental Authority shall have issued an order or taken any other action, in each case, which has become final and
non-appealable and which restrains, enjoins or otherwise prohibits the consummation of the Transaction on substantially similar terms and conditions; 
 (d) by Issuer, if Issuer is not in material breach of its obligations under this Agreement, and if (i) at any time any of the representations and warranties of HPC herein are or become untrue or inaccurate such
that Section 7.2(a) would not be satisfied (treating such time as if it were the Closing for purposes of this Section 8.1(d)) or (ii) there has been a breach on the part of HPC of any covenants or agreements contained in this
Agreement such that Section 7.2(b) will not be satisfied (treating such time as if it were the Closing for purposes of this Section 8.1(d)), and, in both case (i) and case (ii), such breach (if curable) has not been cured within
fifteen (15) days after written notice thereof to HPC; 

 (e) by HPC, if HPC is not in material breach of its obligations under this Agreement, and if (i) at
any time the representations and warranties of Issuer herein become untrue or inaccurate such that Section 7.3(a) would not be satisfied (treating such time as if it were the Closing for purposes of this Section 8.1(e)), or (ii) there
has been a breach on the part of Issuer of any of their respective covenants or agreements contained in this Agreement such that Section 7.3(b) would not be satisfied (treating such time as if it were the Closing for purposes of this
Section 8.1(e)), and, in both case (i) and case (ii), such breach (if curable) has not been cured within fifteen (15) days after written notice thereof to Issuer; 
 (f) by either Issuer or HPC, if, at the Issuer Stockholders’ Meeting at which a vote on this Agreement is taken, approval for the Required Issuer
Vote shall not have been obtained. 
 8.2 Effect of Termination. Except as provided in this Section 8.2, in the event of the
termination of this Agreement pursuant to Section 8.1, this Agreement (other than this Section 8.2 and Section 8.3, each of which shall survive such termination) will forthwith become void, and there will be no liability on the part
of Issuer or HPC or any of its respective representatives to the other and all rights and obligations of any Party will cease, except that nothing herein will relieve any Party from liability for any breach, prior to termination of this Agreement in
accordance with its terms, of any representation, warranty, covenant or agreement contained in this Agreement. 
 8.3 Fees and
Expenses. Except as expressly provided herein, all fees and expenses incurred by the Parties in connection with this Agreement and the transactions contemplated hereby shall be paid by the relevant Party incurring such fees and expenses, whether
or not the Transaction is consummated. 
 8.4 Waiver. At any time prior to the Closing, any Party may extend the time for the
performance of any of the obligations or other acts required hereunder, waive any inaccuracies in the representations and warranties contained herein or in any document delivered pursuant hereto and waive compliance with any of the agreements or
conditions contained herein. Any such extension or waiver shall be valid only if set forth in an instrument signed by the Party to be bound thereby. 
 ARTICLE IX 
 INDEMNIFICATION OF ISSUER 
 9.1 Definitions. As used in this Agreement, the following terms shall have the following meanings: 
 (a) “Article IX Event of Indemnification” shall mean the following: 
 (i) the untruth, inaccuracy or breach of any
representation or warranty contained in ARTICLE II or ARTICLE III of this Agreement; and 
 (ii) the breach of any agreement or covenant of
HPC contained in this Agreement. 

 (b) “Article IX Indemnified Persons” shall mean and include Issuer, successors and
assigns, and the respective officers and directors of each of the foregoing. 
 (c) “Article IX Indemnifying Person” shall
mean HPC and its successors and/or assigns. 
 (d) “Article IX Losses” shall mean any and all losses, claims, shortages,
damages, liabilities, expenses (including attorneys’ and accountants’ fees actually and reasonably incurred, including in respect of any action brought to enforce the indemnity rights under this Article IX) (including interest or penalties
thereon), sustained, suffered or incurred by any Article IX Indemnified Person arising from any such matter that is the subject of indemnification under Section 9.2. 
 9.2 Indemnification Generally. 
 (a) The Article IX Indemnifying Persons shall indemnify and hold
harmless the Article IX Indemnified Persons from and against any and all Article IX Losses arising from or in connection with any Article IX Event of Indemnification. 
 (b) Notwithstanding the foregoing, the Article IX Indemnifying Persons shall not be required to pay any amount with respect to any claim pursuant to Article IX unless and until the aggregate amount of all Article IX
Losses exceeds €1,000,000 (the “Deductible”), in which event the Article IX Indemnifying Persons shall be liable only for the amount of the Article IX Losses in excess of €1,000,000. The provisions of this
Section 9.2(b) shall not apply to any Article IX Losses arising under Section 9.1(a)(i) in respect of breaches of Section 2.1(a), 2.1(b), 2.2, 2.3 or 3.1. 
 (c) Notwithstanding the foregoing, the Article IX Indemnifying Persons shall not be liable for any single or related Article IX Losses that, when taken together with all related Article IX Losses arising out of the
same facts and circumstances, do not exceed €50,000. 
 (d) The Article IX Indemnifying Persons’ aggregate liability for all
Article IX Losses under Article IX shall not exceed the amount of the Escrow Shares, it being provided that (i) two-thirds of the then-remaining Escrow Shares (less the amount of any unsettled claims then pending) shall be released by the
Escrow Agent to HPC within three Business Days following the expiration of the twelve-month anniversary of the Closing Date in accordance with the Escrow Agreement and (ii) the rest of the then-remaining Escrow Shares (less the amount of any
unsettled claims then pending) shall be released by the Escrow Agent to HPC within three Business Days following the Survival Date in accordance with the Escrow Agreement. The provisions of this Section 9.2(d) shall not apply to any Article IX
Losses arising under Section 9.1(a)(i) in respect of breaches of Section 2.1(a), 2.1(b), 2.2, 2.3 or 3.1. 
 (e) Issuer
acknowledges and agrees that the Article IX Indemnifying Persons shall not have any liability under any provision of this Agreement for any Article IX Losses to the extent that such Article IX Losses relate to action taken by Issuer or any other
Person (other than HPC or the Company in breach of this Agreement) after the Closing Date. Issuer shall take and shall cause its affiliates to take all reasonable steps to mitigate any Article IX Losses upon becoming aware of any event which would
reasonably be expected to, or does, give rise thereto. 

 (f) For purposes of calculation of the indemnification due by the Article IX Indemnifying Persons, any
amounts paid or payable to the Article IX Indemnified Persons under insurance policies or any other amount compensating the Article IX Loss for which the claim is made shall be deducted. If the Article IX Indemnifying Persons pay an indemnity in
respect of a Article IX Loss and the Article IX Indemnified Persons subsequently recover all or part of the amount of such indemnity from a third party (including insurance companies or tax authorities), the Article IX Indemnified Persons,
immediately upon recovery thereof, shall pay to the Article IX Indemnifying Persons the amount thereby recovered. 
 (g) Any indemnification
due by the Article IX Indemnifying Persons shall be based on the amount of the Article IX Loss actually suffered by the Article IX Indemnified Persons and shall be computed without regard to any multiple or valuation factor that may have been used
in determining the Purchase Price. If a claim is based upon a liability which is contingent only, no indemnification shall be due unless and until such liability becomes due and payable. 
 (h) Notwithstanding anything to the contrary in this Agreement, the amount of the indemnity due by the Article IX Indemnifying Persons in connection with
an Article IX Loss sustained in relation to Scient’x and its Subsidiaries shall be limited to the 33.1% of such Article IX Loss. 
 9.3
Assertion of Claims. No claim shall be brought under Section 9.2 unless the Article IX Indemnified Persons, or any of them, at any time prior to the Survival Date, give HPC (a) written notice of the existence of any such claim,
specifying the nature and basis of such claim and the amount thereof, to the extent known or (b) written notice pursuant to Section 9.4 of any Article IX Third Party Claim, the existence of which might give rise to such a claim but the
failure so to provide such notice to HPC will not relieve the Article IX Indemnifying Persons from any liability which they may have to the Article IX Indemnified Persons under this Agreement or otherwise (unless and only to the extent that such
failure results in the loss or compromise of any material rights or defenses of the Article IX Indemnifying Persons). Upon the giving of such written notice as aforesaid, the Article IX Indemnified Persons, or any of them, shall have the right to
commence legal proceedings prior or subsequent to the Survival Date for the enforcement of their rights under Section 9.2 hereof. Any claim for indemnification not made by the Article IX Indemnified Persons, or any of them, on or prior to the
Survival Date will be irrevocably and unconditionally released and waived and the Article IX Indemnifying Persons shall cease to be under any liability to the Article IX Indemnified Persons or otherwise in respect to all and any claim not so
notified prior to the Survival Date. 
 9.4 Notice and Defense of Article IX Third Party Claims. Article IX Losses resulting from the
assertion of liability by third parties (each, an “Article IX Third Party Claim”) shall be subject to the following terms and conditions: 
 (a) The Article IX Indemnified Persons shall promptly give written notice to HPC of any Article IX Third Party Claim that might give rise to any Article IX Loss by the Article IX Indemnified Persons, stating the
nature and basis of such Article IX Third Party Claim, and the amount thereof to the extent known. Such notice shall be accompanied by copies of all relevant documentation with respect to such Article IX Third Party Claim, including, without
limitation, any summons, complaint or other pleading that may have been served, any written demand or 

 
any other document or instrument. Notwithstanding the foregoing, the failure to provide notice as aforesaid to HPC will not relieve the Article IX
Indemnifying Persons from any liability which they may have to the Article IX Indemnified Persons under this Agreement or otherwise (unless and only to the extent that such failure results in the loss or compromise of any material rights or defenses
of the Article IX Indemnifying Person). 
 (b) If so requested by the Article IX Indemnifying Persons, the Article IX Indemnified Persons
shall take all reasonable steps or proceedings as the Article IX Indemnifying Persons may reasonably require, at the Article IX Indemnifying Persons’ cost, in order to mitigate, avoid, resist, appeal, dispute, contest, remedy, compromise or
defend any such Article IX Third Party Claim and any adjudication in respect thereof or enforce against any person (other than the Article IX Indemnifying Persons) the rights of the Article IX Indemnified Persons in relation to the matter that
constitutes the subject of the Article IX Third Party Claim. Nothing in this paragraph shall oblige the Article IX Indemnified Persons to pursue any course of action that would materially adversely affect the reputation of the Article IX Indemnified
Persons’ group. Notwithstanding anything in this Article IX to the contrary, HPC shall not settle, compromise or offer to settle or compromise any Article IX Third Party Claim without the prior consent of Issuer, which consent shall not be
unreasonably withheld. Issuer shall not have the right to object to a settlement which consists solely of the payment of a monetary damage amount and which is subject to full indemnification under this ARTICLE IX. 
 (c) The Article IX Indemnifying Persons, on the one hand, and the Article IX Indemnified Persons, on the other hand, shall make available to each other
and their counsel and accountants all books and records and information relating to any Article IX Third Party Claims, keep each other fully apprised as to the details and progress of all proceedings relating thereto and render to each other such
assistance as may be reasonably required to ensure the proper and adequate defense of any and all Article IX Third Party Claims. 
 9.5 Any
payment of any Article IX Losses by and any Article IX Indemnifying Person hereunder shall be treated as a reduction of the Purchase Price. 
 ARTICLE X 
 INDEMNIFICATION OF HPC 
 10.1 Definitions. As used in this Agreement, the following terms shall have the following meanings: 
 (a) “Article X Event of Indemnification” shall mean the following: 
 (i) the untruth, inaccuracy or breach of any
representation or warranty contained in ARTICLE IV of this Agreement; and 
 (ii) the breach of any agreement or covenant of Issuer contained
in this Agreement. 
 (b) “Article X Indemnified Persons” shall mean and include HPC and its successors and permitted
assigns of this Agreement. 

 (c) “Article X Indemnifying Persons” shall mean and include Issuer and its estate.

 (d) “Article X Losses” shall mean any and all losses, claims, shortages, damages, liabilities, expenses (including
attorneys’ and accountants’ fees actually and reasonably incurred, including in respect of any action brought to enforce the indemnity rights under this Article X), (including interest or penalties thereon), sustained, suffered or incurred
by any Article X Indemnified Person arising from any such matter that is the subject of indemnification under Section 10.2. 
 10.2
Indemnification Generally. 
 (a) The Article X Indemnifying Persons shall indemnify and hold harmless the Article X Indemnified
Persons from and against any and all Article X Losses arising from or in connection with any Article X Event of Indemnification, which shall be paid solely in the form of Shares, subject to the additional limitations set forth in this ARTICLE X.

 (b) Notwithstanding the foregoing, the Article X Indemnifying Persons shall not be required to pay any amount with respect to any claim
pursuant to Article X unless the aggregate amount of all Article X Losses exceeds the Deductible, in which event the Article X Indemnifying Persons shall be liable only for the amount of the Article X Losses in excess of the Deductible. The
provisions of this Section 10.2(b) shall not apply to any Article X Losses arising under Section 10.1(a)(i) in respect of breaches of Section 4.1, 4.2, 4.3(a), 4.3(b) or 4.6. 
 (c) Notwithstanding the foregoing, the Article X Indemnifying Persons shall not be liable for any single or related Article X Losses that, when taken
together with all related Article X Losses arising out of the same facts and circumstances, do not exceed €50,000. 
 (d) The Article X
Indemnifying Persons’ liability for any Article X Loss under Article X shall not exceed the number of Shares equal to 10% of the Share Number, it being provided that after the twelve-month anniversary the Article X Indemnifying Persons’
liability hereunder shall not exceed 3 1/3% of the Share Number. The provisions of this Section 10.2(d)
shall not apply to breaches of Section 4.1, 4.2, 4.3(a), 4.3(b) or 4.6. 
 (e) For the avoidance of doubt, any liability of the
Article X Indemnifying Persons hereunder shall be paid and settled by delivery of Shares to the Article X Indemnified Persons. 
 (f) Any
indemnification due by the Article X Indemnifying Persons shall be based on the amount of the Article X Loss actually suffered by the Article X Indemnified Persons. If a claim is based upon a liability which is contingent only, no indemnification
shall be due unless and until such liability becomes due and payable. 
 10.3 Assertion of Claims. No claim shall be brought under
Section 10.2 unless the Article X Indemnified Persons, or any of them, at any time prior to the Survival Date, give Issuer (a) written notice of the existence of any such claim, specifying the nature and basis of such claim and the amount
thereof, to the extent known or (b) written notice pursuant to Section 10.4 of any Article X Third Party Claim, the existence of which might give rise to such a claim but the failure so to provide such notice to Issuer will not relieve the
Article X Indemnifying Persons from any liability which they may have to the Article X Indemnified Persons under this 

 
Agreement or otherwise (unless and only to the extent that such failure results in the loss or compromise of any material rights or defenses of the Article X
Indemnifying Persons). Upon the giving of such written notice as aforesaid, the Article X Indemnified Persons, or any of them, shall have the right to commence legal proceedings prior or subsequent to the Survival Date for the enforcement of their
rights under Section 10.2 hereof. Any claim for indemnification not made by the Article X Indemnified Persons, or any of them, on or prior to the Survival Date will be irrevocably and unconditionally released and waived and the Article X
Indemnifying Persons shall cease to be under any liability to the Article X Indemnified Persons or otherwise in respect to all and any claim not so notified prior to the Survival Date. 
 10.4 Notice and Defense of Article X Third Party Claims. Article X Losses resulting from the assertion of liability by third parties (each, an
“Article X Third Party Claim”) shall be subject to the following terms and conditions: 
 (a) The Article X Indemnified
Persons shall promptly give written notice to Issuer of any Article X Third Party Claim that might give rise to any Article X Loss by the Article X Indemnified Persons, stating the nature and basis of such Article X Third Party Claim, and the amount
thereof to the extent known. Such notice shall be accompanied by copies of all relevant documentation with respect to such Article X Third Party Claim, including, without limitation, any summons, complaint or other pleading that may have been
served, any written demand or any other document or instrument. Notwithstanding the foregoing, the failure to provide notice as aforesaid to Issuer will not relieve the Article X Indemnifying Persons from any liability which they may have to the
Article X Indemnified Persons under this Agreement or otherwise (unless and only to the extent that such failure results in the loss or compromise of any material rights or defenses of the Article X Indemnifying Person). 
 (b) If so requested by the Article X Indemnifying Persons, the Article X Indemnified Persons shall take all reasonable steps or proceedings as the
Article X Indemnifying Persons may reasonably require, at the Article X Indemnifying Persons’ cost, in order to mitigate, avoid, resist, appeal, dispute, contest, remedy, compromise or defend any such Article X Third Party Claim and any
adjudication in respect thereof or enforce against any person (other than the Article X Indemnifying Persons) the rights of the Article X Indemnified Persons in relation to the matter that constitutes the subject of the Article X Third Party Claim.
Nothing in this paragraph shall oblige the Article X Indemnified Persons to pursue any course of action that would materially adversely affect the reputation of the Article X Indemnified Persons’ Group. Notwithstanding anything in this Article
IX to the contrary, Issuer shall not settle, compromise or offer to settle or compromise any Article X Third Party Claim without the prior consent of HPC, which consent shall not be unreasonably withheld. HPC shall not have the right to object to a
settlement which consists solely of the payment of a monetary damage amount and which is subject to full indemnification under this ARTICLE IX. 
 (c) The Article X Indemnifying Persons, on the one hand, and the Article X Indemnified Persons, on the other hand, shall make available to each other and their counsel and accountants all books and records and information relating to any
Article X Third Party Claims, keep each other fully apprised as to the details and progress of all proceedings relating thereto and render to each other such assistance as may be reasonably required to ensure the proper and adequate defense of any
and all Article X Third Party Claims. 

 ARTICLE XI 
 MISCELLANEOUS 
 11.1 Notices. All notices or other communications which are required or
permitted hereunder shall be in writing and sufficient if delivered personally or sent by nationally-recognized overnight courier or by registered or certified mail, postage prepaid, return receipt requested, or by electronic mail, with a copy
thereof to be delivered by mail (as aforesaid) within twenty-four (24) hours of such electronic mail, or by telecopier, with confirmation as provided above addressed as follows: 
  

	 	(a)	If to Issuer: 

 Alphatec Holdings, Inc. 
 2051 Palomar Airport Road 
 Carlsbad, CA 92011

 Telecopier: (760) 431-9083 
 E-Mail: egarner@alphatecspine.com 
 Attention: Ebun S. Garner, Esq., General Counsel 
 With a copy to: 
 Mintz, Levin, Cohn, Ferris,
Glovsky and Popeo, P.C. 
 666 Third Avenue 
 New York, NY 10017 
 Telecopier: (212) 983-3115 
 E-Mail: jmmcknight@mintz.com 
 Attention:
James M. McKnight, Esq. 
  

	 	(b)	If to HPC: 

 c/o HealthpointCapital, LLC 
 505 Park Avenue, 12th
Floor 
 New York, NY 10022 
 Telecopier: (212) 935-6878 
 E-Mail: jfoster@healthpointcapital.com 
 Attn: John H. Foster, Chairman 
 or to such other address as
the party to whom notice is to be given may have furnished to the other party in writing in accordance herewith. All such notices or communications shall be deemed to be received (a) in the case of personal delivery, on the date of such
delivery, (b) in the case of nationally-recognized overnight courier, on the next Business Day after the date when sent (c) in the case of facsimile transmission or telecopier or electronic mail, upon confirmed receipt, and (d) in the
case of mailing, on the date of receipt or refusal. 

 11.2 Interpretation. When a reference is made in this Agreement to Sections, subsections or
Schedules, such reference shall be to a Section, subsection or Schedule to this Agreement unless otherwise indicated. The words “include,” “includes” and “including” when used herein shall be deemed in each case to be
followed by the words “without limitation.” The word “herein” and similar references mean, except where a specific Section or Article reference is expressly indicated, the entire Agreement rather than any specific Section or
Article. The table of contents and the headings contained in this Agreement are for reference purposes only and shall not affect in any way the meaning or interpretation of this Agreement. 
 11.3 Severability. If any term or other provision of this Agreement is invalid, illegal or incapable of being enforced by any rule of law, or
public policy, all other conditions and provisions of this Agreement shall nevertheless remain in full force and effect so long as the economic or legal substance of the transactions contemplated hereby is not affected in any manner adverse to any
party. Upon such determination that any term or other provision is invalid, illegal or incapable of being enforced, the Parties shall negotiate in good faith to modify this Agreement so as to effect the original intent of the Parties as closely as
possible in an acceptable manner to the end that transactions contemplated hereby are fulfilled to the extent possible. 
 11.4 Entire
Agreement. This Agreement (including all schedules hereto), and other documents and instruments delivered in connection herewith constitute the entire agreement and supersede all prior agreements and undertakings, both written and oral, among
the Parties with respect to the subject matter hereof. 
 11.5 Assignment. This Agreement shall not be assigned by operation of law or
otherwise, except that Issuer may assign all or any of their rights hereunder to any affiliate, provided that no such assignment shall relieve the assigning Party of its obligations hereunder. 
 11.6 Parties in Interest. Except as explicitly set forth herein, this Agreement shall be binding upon and inure solely to the benefit of each
Party hereto, and nothing in this Agreement, express or implied, is intended to or shall confer upon any other Person (other than the shareholders of the Company, who are expressly intended to be third party beneficiaries of this Agreement with
respect to the Issuer’s obligations hereunder if the Transaction is consummated) any right, benefit or remedy of any nature whatsoever under or by reason of this Agreement. 
 11.7 Failure or Indulgence Not Waiver; Remedies Cumulative. No failure or delay on the part of any Party in the exercise of any right hereunder
will impair such right or be construed to be a waiver of, or acquiescence in, any breach of any representation, warranty or agreement herein, nor will any single or partial exercise of any such right preclude other or further exercise thereof or of
any other right. All rights and remedies existing under this Agreement are cumulative to, and not exclusive to, and not exclusive of, any rights or remedies otherwise available. 
 11.8 Governing Law; Enforcement. This Agreement shall be governed by, and construed in accordance with, the laws of the State of New York
applicable to contracts executed in and to be performed in that jurisdiction (other than those provisions set forth herein that are required to be governed by the laws of the Grand Duchy of Luxembourg or the State of 

 
Delaware), excluding (to the greatest extent a New York court would permit) any rule of law that would cause the application of the laws of any jurisdiction
other than the State of New York. The Parties agree that irreparable damage would occur in the event that any of the provisions of this Agreement were not performed in accordance with their specific terms or were otherwise breached. It is
accordingly agreed that the Parties shall be entitled to an injunction or injunctions to prevent breaches of this Agreement and to enforce specifically the terms and provisions of this Agreement in the federal or state courts in the city and State
of New York, this being in addition to any other remedy to which they are entitled at law or in equity. In addition, each of the Parties: (a) consents to submit itself to the personal jurisdiction of the federal or state courts of the city and
State of New York in the event any dispute arises out of this Agreement or any transaction contemplated hereby; (b) agrees that it will not attempt to deny or defeat such personal jurisdiction by motion or other request for leave from any such
court; (c) waives any right to trial by jury with respect to any action related to or arising out of this Agreement or any transaction contemplated hereby; and (d) consents to service of process by delivery pursuant to Section 11.1.

 11.9 Certain Definitions. For purposes of this Agreement, unless the context otherwise requires, the term: 
 (a) “affiliate” means a Person that, directly or indirectly, through one or more intermediaries, controls, is controlled by, or is under common
control with, the first mentioned Person; including, but not limited to, any partnership or joint venture in which the Person (either alone, or through or together with any of its Subsidiaries) has, directly or indirectly, an interest of 5% or more.

 (b) “Antitrust Clearances” shall mean the approval, consent, waiver, license, order, registration, permits, ruling,
authorization or clearance of the contemplated transactions from any competent merger control authorities whose approval is required. 
 (c)
“Board” means the board of directors of the Company. 
 (d) “contract” means any contract, plan, undertaking,
understanding, agreement, license, lease, permit, franchise, note, bond, mortgage, indenture, binding commitment or other instrument or obligation, whether written or oral. 
 (e) “control” (including the terms “controlled by” and “under common control with”) means the possession, directly or
indirectly or as trustee or executor, of the power to direct or cause the direction of the management or policies of a Person, whether through the ownership of stock or other securities, as trustee or executor, by contract or credit arrangement or
otherwise. 
 (f) “Escrow Agent” means the escrow agent to be appointed pursuant to the Escrow Agreement. 
 (g) “Escrow Agreement” means an escrow agreement among HPC, Issuer and an escrow agent reasonably mutually acceptable to HPC and Issuer on
terms and conditions reasonably mutually acceptable to HPC and Issuer. 

 (h) “Exchange Act” means the United States Securities Exchange Act of 1934, as amended, and the
rules and regulations promulgated thereunder. 
 (i) “Financing Letter” means the certain letter concerning debt financing for the
Transaction dated September 26, 2006 from Lehman Brothers addressed to Issuer. 
 (j) “HSR Act” means the Hart-Scott-Rodino
Antitrust Improvements Act of 1976, as amended. 
 (k) “Issuer Common Stock Price” will be equal to the arithmetic average of the
volume-weighted average daily trading prices of the Shares on the NASDAQ as they appear on the Bloomberg on-line information service (Code: ATEC) (expressed in U.S. dollars and translated into Euros at each applicable day’s noon buying rate in
New York City for cable transfers in foreign currencies as certified for customs purposes by the Federal Reserve Bank of New York) for 7 U.S. trading days, chosen at random by a French judicial officer from among each period of 30 consecutive
calendar days beginning on the date hereof and ending on the 20th trading day immediately preceding the Issuer
Stockholders’ Meeting, and an additional pro rata number of trading days (not to exceed 7 U.S. trading days) with respect to any final period that is less than 30 consecutive calendar days; provided, however, that in the event that the formula
set forth above would result in a price greater than $9.50 per Share, the result shall be deemed to be $9.50 per Share and in the event that the formula set forth above would result in a price less than $5.00 per Share, the result shall be deemed to
be $5.00 per Share. 
 (l) “Issuer Material Adverse Effect” means any change, event or effect that has material adverse effect on
the business, assets (including, without limitation, intangible assets), financial condition, results of operations or reasonably foreseeable prospects of the Issuer and its Subsidiaries, taken as a whole, excluding any changes, events or effects
that are attributable to: (i) conditions that materially and adversely affect the general worldwide economy, which changes do not disproportionately affect the Issuer and its Subsidiaries; or (ii) conditions that materially and adversely
affect the industries in which the Issuer and its Subsidiaries compete, which changes do not disproportionately affect the Issuer and its Subsidiaries relative to other participants in such industry. For the avoidance of doubt, decreases in the
Issuer’s stock price in and of itself is not an Issuer Material Adverse Effect, provided that this sentence shall not preclude the other Party from asserting that the underlying cause of any such decrease in stock price is an Issuer Material
Adverse Effect. 
 (m) “Issuer Stockholders’ Meeting” means the meeting of the stockholders of the Issuer convened to approve
the Issuer Transactions. 
 (n) “Issuer Transactions” shall mean (i) the issuance of the Shares to HPC, (ii) the Issuer
Subsidiary Merger, and (iii) the offer by the Issuer (or its affiliate or successor) for all the Company Shares not held by the Issuer or any affiliate thereof after the Closing subject to and in accordance with the applicable regulations of
the Autorité des marches financiers. 
 (o) “knowledge” means (i) in the case an individual, knowledge of a
particular fact or other matter if (A) such individual is actually aware of such fact or other matter, or (B) a reasonably prudent individual would become aware of such fact or other matter in the course of 

 
conducting a reasonable investigation concerning the existence of such fact or other matter; (ii) in the case of any other Person (other than an
individual) such Person will be deemed to have knowledge of a particular fact or other matter if any individual who is serving, or has at any time served, as a director, officer, partner, executor, or trustee of such Person (or in any similar
capacity) has, or at any time had, knowledge of such fact or other matter. 
 (p) “Law” or “Laws” means all US, French,
Luxembourg, provincial, state, local and foreign statutes, laws and regulations. 
 (q) “Person” means any natural person,
corporation, partnership, association, trust, unincorporated organization, limited liability company, joint stock company, joint venture, non-corporate business enterprise, or other entity or group (as defined in Section 13(d)(3) of the
Exchange Act). 
 (r) “SEC” means the United States Securities and Exchange Commission. 
 (s) “Subsidiary” means, with respect to any party, any corporation or other organization, whether incorporated or unincorporated, of which
(i) such party (or any other Subsidiary of such party) is a general partner (excluding partnerships, the general partnerships of which held by such party or a Subsidiary of such party do not have a majority of the voting interest of such
partnership) or (ii) at least a majority of the securities or other equity interests having by their terms ordinary voting power to elect a majority of the board of directors or others performing similar functions with respect to such
corporation or other organization, is directly or indirectly owned or controlled by such party or by any one or more of its Subsidiaries, or by such party and one or more of its Subsidiaries. 
 (t) “Substitute Financing” means financing on terms no less advantageous to Issuer, in Issuer’s sole discretion, than the terms set forth
in the Financing Letter. 
 (u) “Survival Date” means the date that is 18 months after the Closing. 
 11.10 Certain Additional Definitions. As used in this Agreement, the following terms shall have the respective meanings ascribed thereto in the
respective sections of this Agreement set forth opposite each such term below: 
  

			
	 Term
	  	Section
	 Agreement
	  	Preamble
		
	 Article IX Event of Indemnification
	  	9.1(a)
		
	 Article IX Indemnified Persons
	  	9.1(b)
		
	 Article IX Indemnifying Persons
	  	9.1(c)
		
	 Article IX Losses
	  	9.1(d)
		
	 Article IX Third Party Claim
	  	9.4
		
	 Article X Event of Indemnification
	  	10.1(a)
		
	 Article X Indemnified Persons
	  	10.1(b)
		
	 Article X Indemnifying Persons
	  	10.1(c)
		
	 Article X Losses
	  	10.1(d)
		
	 Article X Third Party Claim
	  	10.4

			
		
	 Business Day
	  	1.9
		
	 Closing
	  	1.9
		
	 Closing Date
	  	1.9
		
	 Company
	  	Recitals
		
	 Company Annual Report
	  	2.5
		
	 Company Disclosure Schedule
	  	Article II
		
	 Company Shares
	  	Recitals
		
	 Company Material Adverse Effect
	  	Article II
		
	 Closing
	  	1.9
		
	 Closing Date
	  	1.9
		
	 Deductible
	  	9.2(b)
		
	 EC Merger Regulation
	  	2.4
		
	 Equitable Exceptions
	  	3.1
		
	 Escrow Shares
	  	1.4(a)
		
	 Governmental Authority
	  	2.4
		
	 HPC
	  	Preamble
		
	 Issuer
	  	Preamble
		
	 Issuer Board
	  	Recitals
		
	 Issuer Disclosure Schedule
	  	Article IV
		
	 Issuer Material Contracts
	  	4.7(a)
		
	 Issuer Preferred Stock
	  	4.2
		
	 Issuer Stockholders’ Meeting
	  	6.5(a)
		
	 Issuer Subsidiary Merger
	  	Recitals
		
	 Liens
	  	2.3(a)
		
	 Luxco
	  	Recitals
		
	 Luxco Exchange
	  	Recitals
		
	 Merger Sub
	  	Recitals
		
	 OC Acquisition Agreement
	  	Recitals
		
	 OC Exchange
	  	Recitals
		
	 Olivier Carli
	  	Recitals
		
	 Party or Parties
	  	Preamble
		
	 Purchase Price
	  	1.2(b)
		
	 Registration Statement
	  	6.5(a)
		
	 Required Issuer Vote
	  	0
		
	 Scient’x
	  	Recitals
		
	 Scient’x Business Day
	  	1.8
		
	 Scient’x Documents
	  	2.5(b)
		
	 Scient’x Material Contracts
	  	2.6(a)
		
	 Scient’x Option Plans
	  	2.3(b)
		
	 Scient’x Shares
	  	Recitals
		
	 Securities Act
	  	2.3(c)(vii)
		
	 Share Number
	  	1.2
		
	 Shares
	  	Recitals
		
	 Stockholders Agreement
	  	1.7
		
	 Tender Offer
	  	6.7
		
	 Tender Offer Documents
	  	6.9
		
	 Transaction
	  	Recitals

 11.11 Counterparts. This Agreement may be executed in one or more counterparts, and by the
different Parties in separate counterparts, each of which when executed shall be deemed to be an original but all of which taken together shall constitute one and the same agreement. 
 11.12 Language. The Parties hereto confirm that it is their wish that this Agreement, as well as all other documents related hereto, including
legal notices, have been and shall be drawn up in the English language only and that such documents will be construed only in the English language. Les parties confirment leur desir que cet accord ainsi que tous les documents, y compris toutes les
notifications qui s’y rattachent, soient rediges en langue anglaise. 
 IN WITNESS WHEREOF, Issuer and HPC has duly executed this
Agreement as of the date first written above. 
  

			
	ALPHATEC HOLDINGS, INC.
		
	By:	 	 /s/ Ebun S. Garner

	Name:	 	Ebun S. Garner, Esq.
	Title:	 	General Counsel and Vice President
	
	HEALTHPOINTCAPITAL PARTNERS, L.P.
	
	BY: HGP, LLC, its general partner
		
	By:	 	 /s/ John McCormick

	Name:	 	John McCormick
	Title:	 	Managing DirectorAmended and Restated Employement Agreement of Craig D. Sherman

 Exhibit 10.6 
 AMENDED AND RESTATED 
 EMPLOYMENT AGREEMENT 
 BY AND BETWEEN 
 BANCSHARES OF
FLORIDA, INC. 
 AND 
 CRAIG D. SHERMAN 
 THIS AMENDED AND RESTATED EMPLOYMENT AGREEMENT (“Agreement”) is entered into this
1st day of September, 2006, by and between Bancshares of Florida, Inc. (“Bancshares” or
“Employer”) and Craig D. Sherman (“Employee”). Employer and Employee are collectively referred to herein as the “Parties.” 
 RECITALS 
 WHEREAS, Employer wishes to retain Employee as Bancshares’ Chief Loan Officer
and Executive Vice President to perform the duties and responsibilities as are described in this Agreement and as the Employer’s Chief Executive Officer, Chief Operating Officer, Board of Directors (“Board”) may assign to Employee
from time to time; and 
 WHEREAS, Employee desires to be employed by the Employer and to serve as the Employer’s Chief Loan
Officer and Executive Vice President in accordance with the terms and provisions of this Agreement. 
 NOW, THEREFORE, in
consideration of the mutual agreements contained herein and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties hereto represent, warrant, undertake, covenant, and agree as follows:

 OPERATIVE TERMS 
 1.
Employment and Term. Employer shall employ Employee pursuant to the terms of this Agreement to perform the services specified in Section 2 herein. The initial term of employment shall be for a period of two years, commencing on
September 1, 2005 (“Effective Date”). On each anniversary of the Effective Date, this Agreement shall be automatically renewed for one additional year until September 1, 2009, after which there will no further renewals of this
Agreement. Either Party, however, may terminate the renewals of this Agreement at any time by giving the other Party written notice of its intent not to renew. Upon such written notice, the Agreement shall expire at the end of the remaining term.

 The Board or its Compensation Committee shall, annually and prior to any renewal taking place, review Employee’s performance and this
Agreement to determine if the Agreement’s renewals should be continued. The Board’s or its Compensation Committee’s decision shall be included in its meeting minutes. 
 2. Position, Responsibilities, and Duties. During the term of this Agreement, Employee shall devote all of his working time, attention,
skill, and best efforts to accomplish and faithfully perform all of the duties assigned to Employee on a full-time basis. Employee shall, at all times, conduct himself in a manner that will reflect positively upon the Employer. Employee shall obtain
and maintain such licenses, certificates, accreditations, and professional memberships and designations as the Employer may reasonably require. Employee shall notify Employer prior to any significant participation by him in any trade association or
similar organization. Employee shall also have the specific duties prescribed in Schedule A. 
  

 1 

 3. Compensation. During the term of this Agreement, Employee shall be compensated as
described in Schedule B. 
 4. Payment of Business Expenses. Employee is authorized to incur reasonable expenses in
performing his duties hereunder. Employer will reimburse Employee for authorized expenses, according to the Employer’s established policies, promptly after Employee’s presentation of an itemized account of such expenditures. 
 5. Illness or Incapacity. 
 (a) Duration: Employee shall be paid his full Base Salary for any period of his illness or incapacity; provided that such illness or incapacity does not render Employee unable to perform his duties under
this Agreement for a period longer than three consecutive months. At the end of such three-month period, Employer may terminate Employee’s employment and this Agreement, as provided in Section 6(b). 
 (b) Continuation of Coverages: Notwithstanding any contrary provision herein, following any termination of Employee’s
employment and this Agreement pursuant to Section 5(a), the Employer will continue any other life, health, and disability coverages for Employee substantially identical to the coverages maintained prior to Employee’s termination until the
earlier of: 
  

	 	(i)	Employee’s full time employment by another Person; 

  

	 	(ii)	one year after the date of such termination (with the exception of any disability insurance coverage in place, which shall be governed by the terms of such policy); or

  

	 	(iii)	the date of Employee’s death. 

 6.
Termination. 
 (a) Death: This Agreement shall immediately terminate upon Employee’s death,
in which instance Employer shall pay to Employee’s estate any compensation accrued, but not yet paid. 
 (b)
Termination for Cause: The Employer shall have the right, at any time, upon written notice of termination satisfying the requirements of Section 8 herein, to terminate Employee’s employment hereunder, including termination
for Cause as determined by the Board of Directors. A termination for Cause shall be effective immediately upon effectiveness of a notice of termination. For the purpose of this Agreement, termination for “Cause” shall mean termination for:

 (i) personal dishonesty resulting (directly or indirectly) in gain to or personal enrichment of Employee at the expense of Employer,
breach of fiduciary duty, violation of any significant law, rule or regulation, violation of a final cease-and-desist order, or personal default on indebtedness which is not corrected within 30 days from the date of default. 
  

 2 

 (ii) insubordination, conduct unbecoming of a senior officer of a financial institution which could have
a material negative reflection on the Employer, materially failing to perform the duties stated in Schedule A of this Agreement (i.e., failing to perform the essential duties of Employee’s position), 
 In the event Employee is terminated for cause for one of the reasons listed in (i) or (ii), Employee shall have no right to
compensation or other benefits for any period after such date of termination, other than compensation which was accrued, but not yet paid and (in the case of termination pursuant to Section 5[a]) the continuation of coverages and salary as
described in Section 5(b). 
 (c) Other Termination by Employer: If Employee is terminated by Employer
other than for Cause, Employee’s right to severance benefits under this Agreement shall be as set forth in Sections 6(f) and (g) herein. 
 (d) Termination for Good Reason: Employee may terminate his employment hereunder for Good Reason by delivering a notice of termination (as defined in Section 8). For purposes of this Agreement,
“Good Reason” shall mean a failure by Bancshares to comply with any material provision of this Agreement, which failure has not been cured within 15 business days after a notice of such noncompliance has been given by the Employee to
Bancshares. In the event Employee terminates his employment for Good Reason, he shall be entitled to severance benefits as set forth in Sections 6(f) and (g). 
 (e) Termination by Employee: Employee may terminate his employment hereunder and this Agreement for any reason, by providing
a notice of termination (as defined in Section 8). In such event, Employee shall have no right to compensation or other benefits after the date of termination, except for accrued but unpaid compensation. 
 (f) Severance Payment: If Employee is entitled to severance benefits under Sections 6(c) or (d), Employee shall be paid, as
severance, the total Base Salary (as defined in Schedule B) due for the remaining term of this Agreement, but not for a period of less than six months (which is the maximum duration of the agreement not to compete imposed on Employee by
Section 12[b]). Any such payment shall be made in substantially equal semi-monthly installments on the 15th and last days of each month until paid in full and shall only be paid subject to Employee’s execution of a full release in favor of
the Employer for any potential claims related to this Agreement or to Employee’s employment with the Employer. 
 (g)
Additional Severance Benefits: If Employee is entitled to severance benefits under Sections 6(c) or (d), the Employer shall maintain in full force and effect, for the continued benefit of the Employee any Employee benefit plans and
programs in which the Employee was entitled to participate immediately prior to the date of termination for the shorter of: 
  

	 	(i)	one year from the date of termination; or 

  

	 	(ii)	the period of time ending on the date Employee becomes eligible for participation in a comparable plan provided by another employer; provided, however, that the Employee’s
continued participation is possible under the general terms and provisions of such plans and programs. 

  

 3 

 (h) Change-in-Control: This Agreement shall immediately terminate upon a
Change-in-Control (as defined in Schedule B), in which instance Employer shall pay to Employee any compensation accrued, but not yet paid (including any Change-in-Control payment provided for in Schedule B). 
 7. Regulatory Provisions. Employer and Employee acknowledge that the laws and regulations governing the Parties require that the employment
of Employee be governed by certain standards contained in those laws and regulations. To that end, the Parties agree to be bound by the following provisions: 
 (a) Suspension/Temporary Prohibition: If the Employee is suspended and/or temporarily prohibited from participating in the
conduct and affairs of any bank subsidiary of Bancshares by a notice served under Sections 8(e) or (g)(1) of the Federal Deposit Insurance Act (12 U.S.C. §1818[e][3] and [g][1]) Bancshares’ obligations under this Agreement shall be
suspended as of the date of such service unless stayed by appropriate proceedings. If the charges and the notice are dismissed, Bancshares may in its discretion: 
  

	 	(i)	pay the Employee all or part of his compensation withheld while the obligations under this Agreement are suspended; and 

  

	 	(ii)	reinstate (in whole or part) any of Bancshares’ obligations which were suspended. 

 (b) Permanent Prohibition: If the Employee is removed and/or permanently prohibited from participating in the conduct and
affairs of any bank subsidiary of Bancshares by an order issued under Sections 8(e)(4) or (g)(1) of the Federal Deposit Insurance Act (12 U.S.C. §1818[e][4] or [g][1]), all of Bancshares’ obligations under this Agreement shall terminate as
of the effective date of the order, but the Employee’s vested rights, if any shall not be affected. 
 (c) Default
Under FDIA: If any bank subsidiary of Bancshares is in default (as defined in Section 3[x][1] of the Federal Deposit Insurance Act), all obligations under this Agreement shall terminate as of the date of default, but this subsection of
this Agreement shall not affect the Employee’s vested rights if any. 
 8. Notice of Termination. 
 (a) Specificity: Any termination of Employee’s employment by Employer or by Employee shall be communicated by written
notice of termination to the other Party. For purposes of this Agreement, a “notice of termination” shall mean a dated notice which shall: 
  

	 	(i)	indicate the specific relevant termination provision in the Agreement; 

  

	 	(ii)	set forth in reasonable detail the facts and circumstances claimed to provide a basis for termination of Employee’s employment under the provision; and

  

 4 

	 	(iii)	set forth the date of termination, which shall be not less than 30 days nor more than 45 days after such notice of termination is given, unless another Section of the Agreement
requires or permits a different effective date. 

 (b) Delivery of Notices: All notices or
resignations given or required to be given herein shall be in writing, sent by United States first-class certified or registered mail, postage prepaid, by way of overnight carrier, or by hand delivery. If to Employee (or to the Employee’s
spouse or estate upon the Employee’s death) notice shall be sent to Employee’s last-known address, and if to Employer, notice shall be sent to the Employer’s corporate headquarters. All such notices shall be effective five days after
having been deposited in the mail if sent via first-class, certified, or registered mail, or upon delivery if by hand delivery or if sent via overnight carrier. Either Party, by notice in writing, may change or designate the place for receipt of all
such notices. 
 9. Post-Termination Obligations. Employer shall pay to Employee such payments and benefits as are required
pursuant to this Agreement; provided, however, any such payments shall be subject to Employee’s post-termination cooperation. Such cooperation shall include the following: 
 (a) Employee shall furnish such information and assistance as may be reasonably required by Employer in connection with any litigation or
settlement of any dispute between Employer and a customer or other third parties (including without limitation serving as a witness in court or other proceedings); 
 (b) Employee shall provide such information or assistance to Employer in connection with any regulatory examination by any state or
federal regulatory agency; 
 (c) Employee shall keep the Employer’s trade secrets and other proprietary or confidential
information secret to the fullest extent practicable, subject to compliance with all applicable laws; 
 (d) Employee shall
return all Employer’s property, including, but not limited to, keys, credit cards, manuals and other written materials. 
 (e) Employee shall execute a full release of all potential claims related to this Agreement or to Employee’s employment with the Employer in favor of the Employer. 
 Upon submission of proper receipts, Employer shall promptly reimburse Employee for any reasonable expenses incurred by Employee in complying with the
provisions of this Section. 
 10. Indebtedness. If during the term of this Agreement, Employee becomes indebted to Employer or
to one of Employer’s subsidiaries, for any reason, Employer may, at its election, set off and collect any sums due Employee out of any amounts which Employer may owe Employee pursuant to the terms of this Agreement. Furthermore, upon the
termination of this Agreement, all sums owed to Employer by Employee shall become immediately due and payable. Employee shall pay all expenses and Attorneys’ Fees actually or necessarily incurred by Employer in connection with any collection
proceeding for Employee’s indebtedness. Notwithstanding any of the foregoing, any indebtedness to Employer or to one of Employer’s subsidiaries, secured by a mortgage on Employee’s residence shall not be subject to the foregoing
provisions, but shall be governed by the loan documents evidencing such indebtedness. 
  

 5 

 11. Maintenance of Trade Secrets and Confidential Information. Employee shall use his best
efforts and utmost diligence to guard and protect all of the Employer’s (or any of Employer’s subsidiaries) trade secrets and confidential information. Employee shall not, either during the term, or after termination, of this Agreement,
for whatever reason, use in any capacity, or divulge or disclose in any manner, to any Person, the identity of Employer’s (or any of Employer’s subsidiaries) customers, methods of operation, marketing or promotional methods, processes,
techniques, systems, formulas, programs, trade secrets or other confidential information relating to Employer’s (or any of Employer’s subsidiaries) business. Upon termination of this Agreement or Employee’s employment, for any reason,
Employee shall immediately return and deliver to Employer or any of Employer’s subsidiaries, all records and papers and all materials which bear employment trade secrets or confidential information. 
 12. Competitive Activities. 
 (a) Limitation on Outside Activities: Employee agrees that during the term of this Agreement, except with the express consent of the Board, Employee will not, directly or indirectly, engage in,
participate in, become a director of, render advisory or other services to, become employed by, or make any financial investment in any firm, corporation, business entity or business enterprise competitive with or to any business of the Employer.
Notwithstanding the foregoing, Employee shall not be precluded or prohibited from owning passive investments, including investments in the securities of other financial institutions. Employee, however, shall be prohibited from making any investments
or commitments of time, accepting any positions or participating in any activities which cause Employee to devote time to such investments, commitments, positions or activities which interfere with Employee’s position with and obligations to
Bancshares. 
 (b) Agreement Not to Compete: Employee acknowledges that by virtue of his employment with
Employer, Employee will acquire an intimate knowledge of the activities and affairs of Bancshares, including trade secrets and other confidential matters. Employee, therefore, agrees that during the term of this Agreement, and for a period of six
months following the termination of Employee’s employment hereunder, Employee shall not become employed, directly or indirectly, whether as an employee, independent contractor, consultant, or otherwise, with any Financial Institution, located
in any Florida county where a subsidiary of Bancshares has a main office or full-service branch office (“Covered Area”), or with any Person whose intent it is to organize another Financial Institution located in a Covered Area. Employee
acknowledges that this is the same duration of the minimum period that Employee would receive severance benefits under Section 6, if he is entitled to such benefits. 
 Employee further agrees that for a period of 12 months following the termination of Employee’s employment hereunder for any reason,
Employee shall not, directly or indirectly: (i) solicit the business of any then current customer (e.g., borrower or depositor) of the Employer or any of Bancshares’ subsidiaries, regardless of whether or not Employee was responsible for
generating such customer’s business for the Employer or any of Bancshares’ subsidiaries; or (ii) solicit any employees of Employer. 
 Employee hereby agrees that the duration of the anti-competitive covenant set forth herein is reasonable, and that its geographic scope is not unduly restrictive. 
  

 6 

 13. Remedies for Breach. 
 (a) Arbitration: The Parties agree that, except for the specific remedies for Injunctive Relief as contained in
Section 13(b), herein, any controversy or claim arising out of or relating to this Agreement, or any breach thereof, including, without limitation, any claim that this Agreement or any portion thereof is invalid, illegal or otherwise voidable,
shall be submitted to binding arbitration before and in accordance with the Rules of the American Arbitration Association. Judgment upon the determination and/or award of such arbitrator may be entered in any court having jurisdiction thereof;
provided, however, that this clause shall not be construed to permit the award of punitive damages to either Party. The prevailing party to said arbitration shall be entitled to an award of reasonable Attorneys’ Fees. The venue for arbitration
shall be in Collier County, Florida. 
 (b) Injunctive Relief: The Parties acknowledge and agree that the
services to be performed by Employee are special and unique and that money damages cannot fully compensate Employer in the event of Employee’s violation of the provisions of Sections 11 and 12 of this Agreement. Thus, in the event of a breach
of any of the provisions of such Section, Employee agrees that Employer, upon application to a court of competent jurisdiction, shall be entitled to an injunction restraining Employee from any further breach of the terms and provision of such
Section. Should Employer prevail in an action seeking such an injunction, Employee shall pay all costs and Attorneys’ Fees incurred by Employer in and relating to obtaining such injunction. Employee’s sole remedy, in the event of the
wrongful entry of such injunction, shall be the dissolution of such injunction and recovery of Attorneys’ Fees. Employee hereby waives any and all claims for damages by reason of the wrongful issuance of any such injunction. 
 (c) Cumulative Remedies: Notwithstanding any other provision of this Agreement, the injunctive relief described in
Section 13(b) herein and all other remedies provided for in this Agreement which are available to Employer as a result of Employee’s breach of this Agreement, are in addition to and shall not limit any and all remedies existing at law or
in equity which may also be available to Employer. 
 14. Assignment. This Agreement shall inure to the benefit of and be
binding upon the Employee, and to the extent applicable, his heirs, assigns, executors, and personal representatives, and to the Employer, and to the extent applicable, its successors, and assigns, including, without limitation, any Person which may
acquire all or substantially all of Bancshares’ assets and business, or with or into which Bancshares may be consolidated or merged, and this provision shall apply in the event of any subsequent merger, consolidation, or transfer; provided,
however, nothing in this Section 14 shall alter the termination provision of Section 6(h). 
 15. Attorneys’
Fees. In the event that any claim or controversy hereunder is the subject of any litigation or arbitration between the Parties, the prevailing Party shall be entitled to an award of all reasonable costs, including Attorneys’ Fees.

 16. Miscellaneous. 
 (a) Amendment of Agreement: Unless as otherwise provided herein, this Agreement may not be modified or amended except in writing signed by the Parties. 
  

 7 

 (b) Certain Definitions: For purposes of this Agreement, the
following terms whenever capitalized herein shall have the following meanings: 
  

	 	(i)	“Attorneys’ Fees” shall include the reasonable legal fees and disbursements charged by attorneys and their related travel and lodging expenses, court costs, paralegal
fees, etc. incurred in arbitration, mediation, settlement negotiations, discovery, trial, appeal or bankruptcy proceeding. 

  

	 	(ii)	“Person” shall mean any natural person, corporation, partnership (general or limited), trust, association or any other business entity. 

 (c) Headings for Reference Only: The headings of the Sections and the Subsections herein are included solely for convenient
reference and shall not control the meaning or the interpretation of any of the provisions of this Agreement. 
 (d)
Governing Law/Jurisdiction: This Agreement shall be construed in accordance with and governed by the laws of the State of Florida. Any litigation involving the Parties and their rights and obligations hereunder shall be brought in the
appropriate court in Collier County, Florida. 
 (e) Severability: If any of the provisions of this
Agreement shall be held invalid for any reason, the remainder of this Agreement shall not be affected thereby and shall remain in full force and effect in accordance with the remainder of its terms. 
 (f) Entire Agreement: This Agreement and all other documents incorporated or referred to herein, contain the entire
agreement of the Parties and there are no representations, inducements or other provisions other than those expressed in writing herein. No modification, waiver or discharge of any provision or any breach of this Agreement shall be effective unless
it is in writing signed by both Parties. A Party’s waiver of the other Party’s breach of any provision of this Agreement, shall not operate, or be construed, as a waiver of any subsequent breach of that provision or of any other provision
of this Agreement. 
 (g) Waiver: No course of conduct by Employer or Employee and no delay or omission of
Employer or Employee to exercise any right or power given under this Agreement shall: 
  

	 	(i)	impair the subsequent exercise of any right or power, or 

  

	 	(ii)	be construed to be a waiver of any default or any acquiescence in, or consent to, the curing of any default while any other default shall continue to exist, or be construed to be a
waiver of such continuing default or of any other right or power that shall theretofore have arisen. 

 Any power and/or remedy
granted by law and by this Agreement to any Party hereto may be exercised from time to time, and as often as may be deemed expedient. All such rights and powers shall be cumulative to the fullest extent permitted by law. 
 (h) Pronouns: As used herein, words in the singular include the plural, and the masculine include the feminine and
neuter gender, as appropriate. 
  

 8 

 (i) Recitals: The Recitals set forth at the beginning of this Agreement
shall be deemed to be incorporated into this Agreement by this reference as if fully set forth herein, and this Agreement shall be interpreted with reference to and in light of such Recitals. 
 (j) Amendment and Restatement: This Agreement amends and completely restates any other employment agreements by and between
Employee and Bancshares or any of its subsidiaries. By executing this Agreement, Employee completely releases Bancshares and all of its subsidiaries from any obligations under any such other Agreements. 
 IN WITNESS WHEREOF, the Parties hereto have executed this Agreement as of the day and year first written above. 
  

							
	EMPLOYEE	 		 	BANCSHARES OF FLORIDA, INC.
				
	 /s/ Craig D. Sherman
	 		 	By:	 	 /s/ Martin P. Mahan

	Craig D. Sherman	 		 		 	Martin P. Mahan
		 		 		 	Executive Vice President &
		 		 		 	Chief Operating Officer

  

 9 

 SCHEDULE A 
 Employee’s duties shall specifically include, but not be limited to performing the following duties for Bancshares and its subsidiaries (“Company”): 
  

			
	1.	 	Developing and maintaining a high quality loan portfolio;
		
	2.	 	Developing, implementing, and maintaining appropriate credit policies and procedures for the Company;
		
	3.	 	Developing, implementing, and maintaining an appropriate loan review program for the Company;
		
	4.	 	Overseeing and supervising loan servicing and loan administration departments for the Company;
		
	5.	 	Monitoring compliance with loan policies and appropriate regulations for the Company;
		
	6.	 	Providing training for loan personnel for the Company;
		
	7.	 	Participating in overall company-wide management through committee assignments;
		
	8.	 	Providing executive management with reports and loan information, as required;
		
	9.	 	Analyzing financial statements;
		
	10.	 	Administering loan agreements for the Company;
		
	11.	 	Generating monthly and quarterly past due and problem loan reports for the Company;
		
	12.	 	Assisting Company loan officers in structuring credits;
		
	13.	 	Establishing and maintaining credit department policies for the Company;
		
	14.	 	Managing the commercial credit department for the Company;
		
	15.	 	Keeping Bancshares’ Chief Executive Officer and Chief Operating Officer informed of industry developments and regulatory initiatives regarding credit underwriting and making recommendations
on how to improve the commercial credit department; and
		
	16.	 	Coordinating with Bancshares’ attorneys, accountants, and other service providers to the extent necessary to further the business of the Company, keeping in compliance with government laws
and regulations, and otherwise keeping the Company in as good as financial and legal posture as possible.

  

 10 

 SCHEDULE B 
 COMPENSATION 
  

	1.	Base Salary: Employee shall receive an annual salary of $150,000 (the “Base Salary”). Employer may adjust the Base Salary from time to time based upon
the Board’s evaluation of Employee’s performance. In no event, however, will the Base Salary be reduced without Employee’s written concurrence. 

  

	2.	Performance Bonuses: Employee may receive an annual performance bonus at the discretion of the Board which shall not exceed 25% of the Base Salary.

  

	3.	Vacation: Employee is entitled to four weeks paid vacation time per year on a non-cumulative basis. 

  

	4.	Medical Benefits and Other Plans: Employee shall be permitted to participate in all medical and healthcare benefit plans provided by Bancshares to its officers.
Employee shall also be permitted to participate in all other benefit plans offered to senior officers of Bancshares’ subsidiaries. 

  

	5.	Continuing Education: Employer will reimburse Employee for admission or attendance fees for pre-approved educational meetings or seminars offered by such
organizations as the Florida Bankers Association. 

  

	6.	Automobile Allowance: For the initial term of the Agreement, Employee shall be entitled to receive an automobile allowance of $650 per month in accordance with
the Employer’s policies. During any renewal terms, Employer shall increase Employee’s Base Salary by not less than $7,800. 

  

	7.	Change in Control Payment: A “Change-in-Control” of the Employer shall mean the first to occur of any one or more of the following:

  

	 	(i)	any transaction, whether by merger, consolidation, asset sale, recapitalization, reorganization, combination, stock purchase, tender offer, reverse stock split, or otherwise, which
results in the acquisition of, or beneficial ownership (as such term is defined under rules and regulations promulgated under the Securities Exchange Act of 1934, as amended) by any person or entity or any group of persons or entities (other than
the group consisting of a majority of the directors currently serving on the Board of Directors as of the date of this Agreement) “acting in concert,” as contemplated by Section 225.41 of the Federal Reserve Board of Governors’
Regulation Y, of 25% or more of the outstanding shares of common stock of the Employer, or 

  

	 	(ii)	the sale of all or substantially all of the assets of the Employer; or 

  

	 	(iii)	the liquidation of the Employer or a material amount of Employer’s assets; 

  

	 	(iv)	the takeover or control of all or substantially all of the operations of Employer, through any of the means specified above. 

 Upon the occurrence of a Change-in-Control, on the date of closing, Employer shall pay to Employee a lump sum equal to 2.5 times his then current Base
Salary.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00110-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00110-of-00352.parquet"}]]